<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="pmc-domain-id">9</journal-id><journal-id journal-id-type="pmc-domain">ccforum</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11577668</article-id><article-id pub-id-type="pmcid-ver">PMC11577668.1</article-id><article-id pub-id-type="pmcaid">11577668</article-id><article-id pub-id-type="pmcaiid">11577668</article-id><article-id pub-id-type="pmid">39563441</article-id><article-id pub-id-type="doi">10.1186/s13054-024-05150-4</article-id><article-id pub-id-type="publisher-id">5150</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Letao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zinger</surname><given-names initials="J">Julia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sassen</surname><given-names initials="SDT">Sebastiaan D. T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Juffermans</surname><given-names initials="NP">Nicole P.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koch</surname><given-names initials="BCP">Birgit C. P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Endeman</surname><given-names initials="H">Henrik</given-names></name><address><email>h.endeman@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/018906e22</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 992X</institution-id><institution>Department of Hospital Pharmacy, </institution><institution>Erasmus MC-University Medical Center, </institution></institution-wrap>Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.410570.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 6682</institution-id><institution>Department of Hospital Pharmacy, Xinqiao Hospital, </institution><institution>Army Medical University, </institution></institution-wrap>183 Xinqiao Street, Shapingba District, Chongqing, 400037 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/018906e22</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 992X</institution-id><institution>Department of Intensive Care, </institution><institution>Erasmus MC-University Medical Center, </institution></institution-wrap>Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01d02sf11</institution-id><institution-id institution-id-type="GRID">grid.440209.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0501 8269</institution-id><institution>Department of Intensive Care, </institution><institution>OLVG, </institution></institution-wrap>Oosterpark 9, 1091 AC Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>28</volume><issue-id pub-id-type="pmc-issue-id">452038</issue-id><elocation-id>376</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>20</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-22 10:25:34.660"><day>22</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13054_2024_Article_5150.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The level of inflammation alters drug pharmacokinetics (PK) in critically ill patients. This might compromise treatment efficacy. Understanding the specific effects of inflammation, measured by biomarkers, on drug absorption, distribution, metabolism, and excretion is might help in optimizing dosing strategies.</p></sec><sec><title>Objectives</title><p id="Par2">This review investigates the relationship between inflammatory biomarkers and PK parameters absorption, distribution, metabolism and excretion (ADME) in critically ill patients, providing insight in the complexity of dosing drugs in critically ill patients.</p></sec><sec><title>Method</title><p id="Par3">Following PRISMA guidelines, we conducted a comprehensive search of Medline, Embase, Web of Science, and Cochrane databases (January 1946&#8211;November 2023). Studies examining inflammatory biomarkers, PK parameters, or drug exposure in critically ill patients were included. Records were screened by title, abstract, and full text, with any discrepancies resolved through discussion or consultation with a third reviewer.</p></sec><sec><title>Results</title><p id="Par4">Of the 4479 records screened, 31 met our inclusion criteria: 2 on absorption, 7 on distribution, 17 on metabolism, and 6 on excretion. In general, results are only available for a limited number of drugs, and most studies are done only looking at one of the components of ADME. Higher levels of inflammatory biomarkers may increase or decrease drug absorption depending on whether the drug undergoes hepatic first-pass elimination. For drug distribution, inflammation is negatively correlated with drug protein binding capacity, positively correlated with cerebrospinal fluid penetration, and negatively correlated with peritoneal penetration. Metabolizing capacity of most drugs was inversely correlated with inflammatory biomarkers. Regarding excretion, inflammation can lead to reduced drug clearance, except in the neonatal population.</p></sec><sec><title>Conclusion</title><p id="Par5">Inflammatory biomarkers can offer valuable information regarding altered PK in critically ill patients. Our findings emphasize the need to consider inflammation-driven PK variability when individualizing drug therapy in this setting, at the same time research is limited to certain drugs and needs further research, also including pharmacodynamics.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13054-024-05150-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pharmacokinetics</kwd><kwd>Critically ill patient</kwd><kwd>Intensive care unit</kwd><kwd>Inflammation</kwd><kwd>Biomarker</kwd><kwd>CRP</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par39">Inflammation, a key characteristic of critical illness, significantly impacts drug pharmacokinetics (PK). This can lead to challenges in achieving optimal drug dosing, potentially resulting in both under- and overdosing. While clinicians routinely adjust drug doses based on organ function and drug interactions, the influence of inflammation is often overlooked. However, no review has comprehensively summarized the relationship between readily available inflammatory biomarkers and PK parameters in critically ill patients.</p><p id="Par40">Absorption, distribution, metabolism, and excretion (ADME) processes govern drug behavior, this review simplifies these processes with key pharmacokinetic (PK) parameters as shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. A thorough grasp of these PK parameters is essential for implementing precise dosing strategies in clinical practice. This is particularly critical in the context of critically ill patients. An example of this is optimization of antibiotic therapy, especially in relation to the increase in multi-drug resistant pathogens with elevated minimum inhibitory concentrations (MICs). Thus, exploring the factors that influence the intricate relationship between PK is paramount for optimizing dosing strategies and improving patient outcomes in this vulnerable population.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Brief examples about Effect of absorption, distribution, metabolism and extraction (ADME) related pharmacokinetic parameters on pharmacodynamics. t<sub>lag</sub> (lag time): This is the time delay between the administration of a drug and its appearance in the systemic circulation. Ka (Absorption Rate Constant): The rate at which a drug leaves the site of administration and enters the systemic circulation. The higher the Ka, the faster the absorption. Vd (Volume of distribution): This parameter describes the extent to which a drug is distributed into body tissues relative to plasma. CL (clearance): The volume of plasma from which a drug is completely removed per unit time. t<sub>max</sub>: time to reach peak concentration. Cmax: maximum concentration. AUC: area under the curve. C<sub>trough</sub>: trough concentration</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13054_2024_5150_Fig1_HTML.jpg"/></fig></p><p id="Par41">Although the concept of precision dosing has long been mentioned in clinical practice, the application of precision dosing in critically ill patients is still challenging due to the limited pharmacokinetic (PK) studies specifically conducted on critically ill patients. Drugs are prescribed at equivalent doses for both critically ill patients and those who are not critically ill. This practice is based on the assumption that the drug kinetics are comparable in these two groups, resulting in patients frequently receiving identical dosages within the same treatment cycle. However, many studies have shown that critically ill patients exhibit distinct PK parameters compared to those in non-ICU wards [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>], compounded by their highly heterogeneity and dynamically evolving conditions [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. These factors hinder the reliability of existing pharmacokinetic models in predicting drug concentrations in critically ill patients, underscoring the urgent need to identify variables that influence drug PK to enhance precision dosing in this patient group.</p><p id="Par42">Inflammation, a complex biological response triggered by harmful stimuli [<xref ref-type="bibr" rid="CR9">9</xref>], can escalate into a systemic inflammatory response syndrome (SIRS) in critically ill patients, impacting multiple organs and systems [<xref ref-type="bibr" rid="CR10">10</xref>]. This systemic inflammation, often observed in conditions such as sepsis, is characterized by elevated levels of inflammatory markers like C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-&#945;). These biomarkers serve as crucial indicators for the development of complications such as multiple organ dysfunction syndrome (MODS) [<xref ref-type="bibr" rid="CR11">11</xref>], and can also be used to predict and monitor the progression of diseases like acute respiratory distress syndrome (ARDS) and delirium in the ICU [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par43">Existing research has demonstrated that inflammation can trigger changes in a patient&#8217;s physiological state that might change the drug pharmacokinetics [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Recent studies in non-ICU wards have revealed a significant correlation between inflammatory status and drug PK [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>]. Numerous studies have demonstrated a significant association between inflammatory biomarkers and the activity of hepatic cytochrome P450 (CYP) enzymes and membrane transporters, key components of drug metabolism and disposition [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>]. Given that inflammation is more prevalent and more intense among critically ill patients-often triggered by infections, surgeries, severe burns, trauma, or tumors [<xref ref-type="bibr" rid="CR37">37</xref>]-this relationship warrants closer examination in the critical care setting. The intensity of inflammation in the critically ill together with the frequent occurrence of organ failure renders extrapolating of these findings from non-ICU ward patients to critically ill patients uncertain.</p><p id="Par44">Inflammatory biomarkers propose a promising approach for assessing severity of the inflammatory response, organ function and disease progression in greater detail [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>]. Understanding the intricate relationship between drug exposure and changes in biomarker dynamics is critical for advancing precision dosing strategies in critically ill populations [<xref ref-type="bibr" rid="CR41">41</xref>].A deeper insight into this relationship is crucial, as it holds the potential to refine precision dosing strategies in critically ill patients thereby improving patient outcomes.</p><p id="Par45">Thus, this review endeavors to synthesize the existing evidence regarding the relation between inflammatory biomarkers and pharmacokinetics in critically ill patients. The purposes of this study are to reveal how inflammation changes drug behavior in this vulnerable patient group, which may provide inspiration for future pharmacokinetic clinical trials in critically ill patients that ultimately improve patient outcomes in the future.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Search strategy</title><p id="Par46">This review was conducted in line with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We performed a comprehensive search of databases including Medline, EMBASE, Web of Science Core Collection, and the Cochrane Library to gather all relevant articles discussing the influence of inflammatory biomarkers on the PK of critically ill patients. The search combined terms for (1) pharmacokinetics or pharmacodynamics, (2) inflammation or inflammatory markers such as TNF-alpha or interleukins, and (3) intensive care or critical illness. The search, limited to articles published in English, was completed by November 2023 and carried out independently by two researchers (LL and JZ). All selected articles were independently reviewed by LL and JZ. Disagreements were resolved by a third senior reviewer (SS). The specific search terms employed are detailed in Supplementary File <xref rid="MOESM2" ref-type="media">1</xref>.</p></sec><sec id="Sec4"><title>Eligibility criteria</title><p id="Par47">The initial screening involved examining the titles and abstracts of the retrieved studies by two independent researchers, with the exclusion of irrelevant articles. The inclusion criteria were as follows: original, peer-reviewed articles focusing on PK research in ICU settings, which incorporated at least one inflammatory biomarker over time as outlined in our search strategy (Supplementary File <xref rid="MOESM2" ref-type="media">1</xref>). Titles and abstracts were scrutinized to identify pertinent studies. Exclusion criteria included articles not pertaining to ICU settings, review papers, case studies and studies without biomarkers. Additionally, reference lists of selected studies were reviewed to identify further relevant articles. All references from these searches were managed using Endnote X9<sup>&#174;</sup>.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par48">For each included study, we extracted and collated key data comprising the author(s), year of publication, study drugs involved, number of participants, and specific effects of the biomarker(s) on the drug&#8217;s absorption, distribution, metabolism, and excretion (ADME).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par49">The process of selecting studies for our review is comprehensively outlined in Supplementary File <xref rid="MOESM2" ref-type="media">1</xref>. Initially, a search of the relevant literature on the impact of inflammation on pharmacokinetics in the critically ill yielded 6,321 articles. After removing duplicates using the &#8220;Bramer method&#8221; in EndNote [<xref ref-type="bibr" rid="CR42">42</xref>], we screened the titles and abstracts of 4,479 articles. This led to the identification of 190 studies that fulfilled our eligibility criteria and were subjected to a full-text review. Ultimately, 31 papers were included in our analysis, based on inclusion and exclusion criteria, as illustrated in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>PRISMA flow diagram. Snowballing is a method of tracking down relevant publications using the bibliography or reference list at the end of an article as a starting point</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13054_2024_5150_Fig2_HTML.jpg"/></fig></p><sec id="Sec7"><title>Absorption</title><p id="Par50">The current research exploring the impact of inflammation on drug absorption is scarce. However, our review identified two drugs, prasugrel [<xref ref-type="bibr" rid="CR43">43</xref>] and tobramycin [<xref ref-type="bibr" rid="CR44">44</xref>], that exhibit a correlation between their systemic exposure and CRP levels, albeit in different ways (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The active metabolite of prasugrel was inversely correlated with CRP levels, which may indicate a reduced absorption of the metabolite into the systemic circulation. This finding is consistent with another antiplatelet medication, clopidogrel, whose bioavailability was lower in critically ill patients [<xref ref-type="bibr" rid="CR45">45</xref>]. In contrast, tobramycin which administered enteral 6&#160;mg of four times daily, used for selective digestive tract decontamination, showed an opposite trend. Increased CRP levels were associated with increased tobramycin levels (maximum concentration range from 0.27 to 1.3&#160;mg/L) in the blood, which may indicate tobramycin leakage from the gut related to shock due to extensive inflammation [<xref ref-type="bibr" rid="CR44">44</xref>]. This finding is particularly significant, considering another study reported instances of acute renal failure potentially linked to tobramycin intoxication during the decontamination process [<xref ref-type="bibr" rid="CR46">46</xref>]. No studies reported on the effect of inflammation on drug absorption subcutaneously or by other routes. These studies did not explore the relationship between inflammatory biomarkers and drug Cmax and tmax, and therefore could not reflect the effect of inflammation on drug absorption rate. These varied correlations highlight the complex and drug-specific nature of how inflammation can influence drug absorption and systemic exposure.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Inflammation effect on drug absorption*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Time</th><th align="left" colspan="1" rowspan="1">Patient</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Biomarker</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Relationship of biomarker and parameter</th><th align="left" colspan="1" rowspan="1">influence on concentration</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antiplatelet agents</td><td align="left" colspan="1" rowspan="1">Prasugrel [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Adults</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">128 (IQR 89&#8211;164) (mg/l)</td><td align="left" colspan="1" rowspan="1">Prasugrel active metabolites concentration</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">inflammation will lower prasugrel active metabolite</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Tobramycin [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Adults</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">26.0 (IQR 3.0 to 160.6) (mg/l)</td><td align="left" colspan="1" rowspan="1">Tobramycin concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">Inflammation will increase the systematic tobramycin exposure</td></tr></tbody></table><table-wrap-foot><p>Table shows medians and ranges(), unless specified otherwise</p><p><italic toggle="yes">IQR</italic> interquartile range</p><p>*More detailed contents in table can be found in the supplementary excel file</p></table-wrap-foot></table-wrap></p><p id="Par51">So research on absorption is scarce and at the same time there are numerous parameters in critically ill patients who will have an effect on absorption which are related to inflammation [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. Many critically ill patients suffer of impaired motility of the digestive tract, including gastroparesis, which might result in limited passage of drugs from the stomach to the lower digestive tract [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The function of the latter is also impaired many times: transit time is decreased, or increased, and permeability can be affected by impaired mesenteric blood flow and intestinal edema [<xref ref-type="bibr" rid="CR53">53</xref>]. Microbiome will be altered due to the cause of disease, medication, of critical illness itself, resulting in altered enteral metabolism [<xref ref-type="bibr" rid="CR54">54</xref>]. Next to this, pH of the stomach will be increased, etc.</p><p id="Par52">Take home messages for drug absorption: in general, though literature is limited, one should take into account that there are numerous processes in the inflamed critically ill patients that hamper enteral absorption, in particular: (1) For oral drugs that require hepatic metabolism for activation, dose adjustments may be necessary in patients with high levels of inflammation. (2) Be cautious when administering drugs intended for local gastrointestinal action (e.g., selective digestive decontamination) to patients with elevated inflammation. (3) Whenever feasible, consider TDM for oral drugs in critically ill patients to ensure optimal exposure and mitigate potential adverse events due to the high variability in their PK.</p></sec><sec id="Sec8"><title>Distribution</title><p id="Par53">Table <xref rid="Tab2" ref-type="table">2</xref> delineates the impact of inflammation on the distribution of various drugs, including those processed via hepatic and renal pathways [<xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref>]. A notable finding is the positive correlation between inflammatory markers, such as WBC [<xref ref-type="bibr" rid="CR60">60</xref>] and ESR [<xref ref-type="bibr" rid="CR56">56</xref>], and the drugs&#8217; volume of distribution (Vd). This correlation suggests that escalating levels of inflammation may lead to glycocalyx injury and endothelial disruption, resulting in increased extracellular body water and enhanced fluid translocation. Consequently, to achieve a goal concentration, an increase in the initial dose may be required. Specifically, in a drug with high protein binding, such as temocillin, CRP demonstrates a significantly negative correlation with the binding capacity of plasma proteins, resulting in an increased unbound fraction of the drug [<xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, our analysis shows that inflammation might facilitate the penetration of certain drugs, like meropenem [<xref ref-type="bibr" rid="CR58">58</xref>], and morphine metabolites [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] into the cerebrospinal fluid (CSF). Conversely, amphotericin B presents a contrasting scenario [<xref ref-type="bibr" rid="CR59">59</xref>]. Its peritoneal concentration is inversely related to CRP levels, indicating a decrease in its ability to penetrate the peritoneal cavity as inflammation levels rise.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Inflammation effect on drug distribution*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Time</th><th align="left" colspan="1" rowspan="1">Patient</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Biomarker</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Relationship of biomarker and parameter</th><th align="left" colspan="1" rowspan="1">influence on concentration</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Chloramphenicol [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">Children</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">WBC</td><td align="left" colspan="1" rowspan="1">9.79&#8201;&#177;&#8201;3.71 (SD) (10<sup>3</sup>/mm<sup>3</sup>)</td><td align="left" colspan="1" rowspan="1">Vd/F</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">high WBC may lower the Cmax</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Amikacin [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">ESR</td><td align="left" colspan="1" rowspan="1">53 (IQR 33.1&#8211;77.3) (mm/hour)</td><td align="left" colspan="1" rowspan="1">Vd</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">high WBC may lower the Cmax</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Temocillin [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">ICU group: 179 (range 50.9&#8211;550) (mg/L)</td><td align="left" colspan="1" rowspan="1">Protein binding</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher free unbound concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Amphotericin B [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="1" rowspan="1">2007</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Peritoneal concentration</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have lower peritoneal concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Meropenem [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">IL-6</td><td align="left" colspan="1" rowspan="1">4855 (IQR 273&#8211;5000) (pg/mL)</td><td align="left" colspan="1" rowspan="1">CSF concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">high IL-6 will have high CSF concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Analgesics</td><td align="left" colspan="1" rowspan="1">Morphine [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">IL-6</td><td align="left" colspan="1" rowspan="1"><p>Plasma: open vs endovascular surgery</p><p>105 (IQR 40&#8211;256); 29 (IQR 16&#8211;70) (pg/mL)</p><p>CSF: open vs endovascular surgery</p><p>79 (IQR 26&#8211;133); 16 (IQR 9&#8211;80) (pg/mL)</p></td><td align="left" colspan="1" rowspan="1">CSF morphine metabolites concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">high IL-6 will have higher morphine metabolites conentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Analgesics</td><td align="left" colspan="1" rowspan="1">Morphine [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left" colspan="1" rowspan="1">2009</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">IL-6</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">CSF morphine metabolites concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">CSF IL-6 correlate with higher morphine metabolites</td></tr></tbody></table><table-wrap-foot><p>Table shows medians and ranges(), unless specified otherwise</p><p><italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">NA</italic> not available, <italic toggle="yes">Vd</italic> volume of distribution, <italic toggle="yes">WBC</italic> white blood cell, <italic toggle="yes">ESR</italic> erythrocyte sedimentation rate, <italic toggle="yes">CSF</italic> cerebrospinal fluid</p><p>*More detailed contents in table can be found in the supplementary excel file</p></table-wrap-foot></table-wrap></p><p id="Par54">Critically ill patients often experience significant fluid shifts into interstitial spaces, which can significantly alter drug exposure by increasing their volume of distribution, especially for those hydrophilic drugs like aminoglycosides and beta-lactams [<xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR82">82</xref>]. However, few studies have quantitatively explored the relationship between inflammatory biomarkers and peak concentrations. In addition, studies have shown that drug concentrations at the target site may not be consistently reflected in blood levels [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]. Inflammation may significantly influence the distribution and penetration processes, potentially resulting in altered peak and target drug concentrations.</p><p id="Par55">Numerous physiological factors can influence drug distribution in critically ill patients. These include fluid sequestration, weight changes, albumin levels and neurological pathology, all of which can be significantly impacted by systemic inflammation. The systemic inflammatory response syndrome (SIRS) has been associated with increased fluid sequestration [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], resulting fluid accumulation and impaired fluid removal can significantly alter the volume of distribution for many drugs. Moreover, body weight changes in critically ill patients, often attributed to fluid balance [<xref ref-type="bibr" rid="CR88">88</xref>], can further complicate drug dosing. Furthermore, hypoalbuminemia is common in critically ill patients, and high levels of inflammation are often associated with low albumin levels [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>], which may significantly affect the concentrations of highly protein-bound drugs. In addition, neurological pathology and alterations in the blood&#8211;brain barrier (BBB) during systemic inflammation can impact drug penetration, leading to endothelial cell damage and associated with cerebral edema, which lead to altered drug distribution [<xref ref-type="bibr" rid="CR91">91</xref>&#8211;<xref ref-type="bibr" rid="CR94">94</xref>]. Lastly, inflammation is associated with glycocalyx degradation which could lead to microcirculatory dysfunction, thus influencing the target drug concentration [<xref ref-type="bibr" rid="CR95">95</xref>]. These complex interactions between inflammation and various physiological factors underscore the challenges of achieving optimal drug dosing in critically ill patients.</p><p id="Par56">Inflammation influence drug distribution through multifaceted mechanisms affecting both drug-binding proteins and transporters. The acute-phase response elevates AAG levels [<xref ref-type="bibr" rid="CR96">96</xref>], potentially altering the free fraction of drugs bound to it, impacting their distribution and efficacy. Concurrently, inflammation affects the blood&#8211;brain barrier by downregulating efflux transporters such as P-gp, BCRP, and MRP2 [<xref ref-type="bibr" rid="CR97">97</xref>], promoting drug penetration into the CNS and potentially influencing drug pharmacokinetics and pharmacodynamics in inflammatory conditions. However, it is crucial to note that research specifically investigating these effects in the ICU setting remains limited. These complex relationships between inflammation and drug distribution emphasize the need for more relevant studies in future.</p><p id="Par57">Take home messages for drug distribution: In general, distributive volume is highly variable in the critically ill patients with high levels of inflammatory biomarkers. Distribution volume can be higher due to volume resuscitation, lower due to excessive fluid loss, protein binding is altered due to altered albumin levels, interaction, etc. and permeability of vessels, but also barriers, including the blood&#8211;brain barrier will be changed. In particular: (1) For patients with more severe inflammation, highly hydrophilic drugs may require higher loading doses. (2) Be careful for high protein binding drugs, which inflammation might cause large free drug concentration change. 3. Inflammation might change the drug penetration ability, but may have different effect in different sites.</p></sec><sec id="Sec9"><title>Metabolism</title><p id="Par58">Our findings show that inflammation affects metabolism of a diverse array of drugs, as shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The general trend in the relationship between inflammation and metabolism is that increased levels of inflammation are associated with decreased drug clearance, resulting in increased drug exposure, with the exception of two drugs, chloramphenicol and tramadol. This phenomenon is not limited to drugs metabolized by phase-I enzymes like Cytochrome P450 enzymes (CYP) but also extends to those primarily processed by phase-II enzymes like UDP-glucuronosyltransferase (UGT), including chloramphenicol [<xref ref-type="bibr" rid="CR60">60</xref>] and haloperidol [<xref ref-type="bibr" rid="CR98">98</xref>]. In the case of chloramphenicol, although there is a positive correlation between WBC counts and creatinine clearance, the augmentation in the Vd is more substantial compared to the increase in CL. This suggests that, overall, there is a decrease in the drug&#8217;s elimination rate. A notable exception is found with tramadol, metabolized by CYP2B6, where its metabolite levels are elevated during inflammation, as indicated by lower cholinesterase activity [<xref ref-type="bibr" rid="CR99">99</xref>]. This observation aligns with the findings of Camille Lenoir et al., who reported increased CYP2B6 enzyme activity during acute inflammation [<xref ref-type="bibr" rid="CR100">100</xref>].<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Inflammation effect on drug metabolism*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Time</th><th align="left" colspan="1" rowspan="1">Patient</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Biomarker</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Relationship of biomarker and parameter</th><th align="left" colspan="1" rowspan="1">influence on concentration</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Chloramphenicol [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">Children</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">WBC</td><td align="left" colspan="1" rowspan="1">9.79&#8201;&#177;&#8201;3.71 (SD) (10<sup>3</sup>/mm<sup>3</sup>)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">High WBC will may have lower drug exposure</td></tr><tr><td align="left" colspan="1" rowspan="1">Corticosteroid</td><td align="left" colspan="1" rowspan="1">Dexamethasone [<xref ref-type="bibr" rid="CR117">117</xref>]</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">20 (range 0.6&#8211;449) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher dexamethasone concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antipsychotic</td><td align="left" colspan="1" rowspan="1">Haloperidol [<xref ref-type="bibr" rid="CR98">98</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">171 (range 4.1&#8211;368) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher haloperidol concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antineoplastic agent</td><td align="left" colspan="1" rowspan="1">Imatinib [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">134</td><td align="left" colspan="1" rowspan="1">AAG and CRP</td><td align="left" colspan="1" rowspan="1"><p>AAG: 1.96 (IQR 1.6&#8211;2.3) (g/L)</p><p>CRP: 110 (IQR 63&#8211;171) (mg/L)</p></td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1"><p>High AAG have high Imatinib AUC;</p><p>High CRP have high Imatinib AUC</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Antiretroviral</td><td align="left" colspan="1" rowspan="1">Lopinavir [<xref ref-type="bibr" rid="CR118">118</xref>]</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">92</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">65 (IQR 36&#8211;113) (mg/L)</td><td align="left" colspan="1" rowspan="1">Plasma concentrations</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">High CRP will have higher lopinavir concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzodiazepine</td><td align="left" colspan="1" rowspan="1">Midazolam [<xref ref-type="bibr" rid="CR119">119</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">IL-6</td><td align="left" colspan="1" rowspan="1">109 (range 2&#8211;5987) (pg/mL)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High IL-6 will have higher midazolam concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzodiazepine</td><td align="left" colspan="1" rowspan="1">Midazolam [<xref ref-type="bibr" rid="CR120">120</xref>]</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Neonate and children</td><td align="left" colspan="1" rowspan="1">83</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">32 (range 0.3&#8211;385) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher midazolam concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzodiazepine</td><td align="left" colspan="1" rowspan="1">Midazolam [<xref ref-type="bibr" rid="CR121">121</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">113.6 (mg/L)</td><td align="left" colspan="1" rowspan="1">&#945;-hydroxymidazolam/midazolam plasma ratio</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have lower midazolam metabolite concentration and CYP3A activity</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzodiazepine</td><td align="left" colspan="1" rowspan="1">Midazolam [<xref ref-type="bibr" rid="CR122">122</xref>]</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Children and adult</td><td align="left" colspan="1" rowspan="1">136</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher midazolam concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzodiazepine</td><td align="left" colspan="1" rowspan="1">Midazolam [<xref ref-type="bibr" rid="CR123">123</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Children</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">37.5 (range 5&#8211;306) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will have higher midazolam concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Barbiturate</td><td align="left" colspan="1" rowspan="1">Pentobarbital [<xref ref-type="bibr" rid="CR124">124</xref>]</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Neonates and children</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">Validation group: 193 (IQR 75&#8211;295) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High CRP will indicate high Pentobarbital concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Analgesic</td><td align="left" colspan="1" rowspan="1">Tramadol [<xref ref-type="bibr" rid="CR99">99</xref>]</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">ChE</td><td align="left" colspan="1" rowspan="1">Normal 6,171 (IQR 4777&#8211;6635); Low: 3230 (IQR 2837.5&#8211;2766.5) (U L<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">N-demethyltramadol AUC</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">systemic inflammation associated with higher tramadol metabolites</td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Voriconazole [<xref ref-type="bibr" rid="CR125">125</xref>]</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Plasma concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">CRP value&#8201;&gt;&#8201;100&#160;mg/L associated with voriconazole concentrations&#8201;&gt;&#8201;5.5&#160;mg/dL</td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Voriconazole [<xref ref-type="bibr" rid="CR126">126</xref>]</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Plasma concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">Higher CRP were associated with higher trough concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Voriconazole [<xref ref-type="bibr" rid="CR127">127</xref>]</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">CRP and PCT</td><td align="left" colspan="1" rowspan="1"><p>CRP: 73.6 (IQR 35.2&#8211;166.1) (mg/dL)</p><p>PCT: 0.38 (IQR 0.10&#8211;1.03) (ng/mL)</p></td><td align="left" colspan="1" rowspan="1">Voriconazole metabolites</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1"><p>CRP value&#8201;&gt;&#8201;114.6&#160;mg/L was associated with Cmin&#8201;&gt;&#8201;3&#160;mg/L;</p><p>PCT value&#8201;&gt;&#8201;0.3&#160;ng/mL was associated with Cmin&#8201;&gt;&#8201;3&#160;mg/L</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Voriconazole [<xref ref-type="bibr" rid="CR128">128</xref>]</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">103.79&#8201;&#177;&#8201;83.72 (SD) (mg/L)</td><td align="left" colspan="1" rowspan="1">Plasma concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">Higher CRP were associated with higher trough concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Voriconazole [<xref ref-type="bibr" rid="CR129">129</xref>]</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">91 (range 0.3&#8211;434) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">Higher CRP were associated with higher trough concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Anticonvulsant</td><td align="left" colspan="1" rowspan="1">Phenytoin [<xref ref-type="bibr" rid="CR130">130</xref>]</td><td align="left" colspan="1" rowspan="1">1997</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">IL-6</td><td align="left" colspan="1" rowspan="1">11.4&#8201;&#177;&#8201;186.0&#160;pg/ml</td><td align="left" colspan="1" rowspan="1">maximum velocity (Vmax) of phenytoin metabolism</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">High levels of IL-6 associated with high phenytoin concentration</td></tr></tbody></table><table-wrap-foot><p>Table shows medians and ranges(), unless specified otherwise</p><p><italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">NA</italic> not available, <italic toggle="yes">WBC</italic> white blood cell, <italic toggle="yes">CL</italic> clearance, <italic toggle="yes">AAG</italic> alpha-1-acid glycoprotein, <italic toggle="yes">ChE</italic> cholinesterase activity, <italic toggle="yes">AUC</italic> area under the plasma drug concentration&#8211;time curve</p><p><sup>*</sup>More detailed contents in table can be found in the supplementary excel file</p></table-wrap-foot></table-wrap></p><p id="Par59">For drugs that eliminated by liver, inflammation may influence these drug in two primary ways: by altering hepatic blood flow, which impacts drugs with high extraction rates (e.g., morphine, propofol) [<xref ref-type="bibr" rid="CR101">101</xref>], or by modifying hepatic enzyme activity, affecting drugs with low extraction rates (e.g., midazolam, ceftriaxone) [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par60">Most current research focusing on the impact of inflammation on drug pharmacokinetics has been centered on the metabolism phase [<xref ref-type="bibr" rid="CR104">104</xref>] [<xref ref-type="bibr" rid="CR105">105</xref>&#8211;<xref ref-type="bibr" rid="CR109">109</xref>]. Consistent with this, inflammatory biomarkers such as IL-6, TNF-&#945;, and CRP negatively correlate with CYP drug metabolizing capacity [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR113">113</xref>]. In contrast, increased hepatic blood flow in critically ill patients, combined with minimally affected phase-II metabolism, can lead to unchanged or even enhanced drug clearance [<xref ref-type="bibr" rid="CR114">114</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref>]. Our review showed that in critically ill patients with high levels of inflammatory biomarkers often exhibit reduced clearance of drugs metabolized by the liver, raising the risk of drug overexposure [<xref ref-type="bibr" rid="CR113">113</xref>]. Key treatment areas in the ICU, such as anti-inflammatory, sedative, analgesic, anticoagulant, antiarrhythmic, and anti-infection therapies, largely depend on liver metabolism and have narrow therapeutic windows. These findings collectively underscore the multifaceted ways inflammation can impact drug metabolism, significantly influencing drug concentrations in critically ill patients.</p><p id="Par61">Take home messages on metabolism: In general the clinician should be aware that metabolism is altered due to inflammation [<xref ref-type="bibr" rid="CR16">16</xref>] and dose adjustments possibly necessary but highly complex. In particular For drugs undergo hepatic elimination, lower maintenance doses may be needed during periods of high inflammation. Once inflammation resolves, these adjustments should be reversed to maintain optimal efficacy. For high first pass drugs, they should dose lower, since inflammation will inhibit drug metabolism. However, if the drug has active metabolites, should dose higher.</p></sec><sec id="Sec10"><title>Excretion</title><p id="Par62">Drugs and their metabolites are eliminated via multiple excretory routes, such as renal (urine), hepatic (bile), and through excretion in sweat, saliva, gastrointestinal secretions, expired air from the lungs, tears, and breast milk. In critically ill patients, we found that the presence of inflammation greatly affected on drug excretion through the kidneys, as shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. For instance, beta-lactam antibiotics such as meropenem and piperacillin show higher drug concentrations in the presence of elevated levels of inflammatory biomarkers. However, the anticoagulant nadroparin exhibits decreased exposure under conditions of increased inflammation. Similarly, it is observed with vancomycin in neonates, where high inflammation correlates with increased drug clearance and consequently lower drug concentrations which might be due to fluid overload, capillary leak, and renal hyper filtration.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Inflammation effect on drug excretion*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Time</th><th align="left" colspan="1" rowspan="1">Patient</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Biomarker</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Relationship of biomarker and parameter</th><th align="left" colspan="1" rowspan="1">influence on concentration</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antifungal</td><td align="left" colspan="1" rowspan="1">Flucytosine [<xref ref-type="bibr" rid="CR149">149</xref>]</td><td align="left" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">Thrombocyte nadir</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">Thrombocyte nadir are negatively correlated with drug exposure</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Linezolid [<xref ref-type="bibr" rid="CR150">150</xref>]</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">Fibrinogen</td><td align="left" colspan="1" rowspan="1">(Range 2.6&#8211;24.4) (&#956;mol/liter)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1">decrease fibrinogen is associated with linezolid concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Meropenem [<xref ref-type="bibr" rid="CR139">139</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">106.5 (12&#8211;383) (mg/L)</td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">high CRP will indicate high meropenem concentration</td></tr><tr><td align="left" colspan="1" rowspan="1">Anticoagulants</td><td align="left" colspan="1" rowspan="1">Nadroparin [<xref ref-type="bibr" rid="CR151">151</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">CRP, D-dimers</td><td align="left" colspan="1" rowspan="1"><p>CRP 61.0 (IQR 32.5&#8211;101) (mg/L)</p><p>D&#8208;dimer 1.24 (IQR 0.85&#8211;2.18) (mg/L)</p></td><td align="left" colspan="1" rowspan="1">CL</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1"><p>CRP and D-dimers will lead to decrease nadroparin;</p><p>Corticosteroids will lead to increase nadroparin exposure</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Piperacillin [<xref ref-type="bibr" rid="CR152">152</xref>]</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">160</td><td align="left" colspan="1" rowspan="1">CRP and IL-6</td><td align="left" colspan="1" rowspan="1"><p>CRP (range 11&#8211;605) (mg/L)</p><p>IL-6 (range 4&#8211;35,500) (pg/mL)</p></td><td align="left" colspan="1" rowspan="1">Plasma concentration</td><td align="left" colspan="1" rowspan="1">Positive</td><td align="left" colspan="1" rowspan="1"><p>High CRP will indicate toxic concentration while low might indicate subtherapeutic conentration;</p><p>IL-6 low might indicate subtherapeutic concentration</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Antibiotic</td><td align="left" colspan="1" rowspan="1">Vancomycin [<xref ref-type="bibr" rid="CR153">153</xref>]</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Neonatal</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">CRP</td><td align="left" colspan="1" rowspan="1">13.5 (IQR 5&#8211;41.5) (mg/L)</td><td align="left" colspan="1" rowspan="1">Plasma concentration</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">systemic inflammation will lead to low vancomycin concentration</td></tr></tbody></table><table-wrap-foot><p>Table shows medians and ranges(), unless specified otherwise</p><p><italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">CL</italic> clearance, <italic toggle="yes">NA</italic> not available</p><p><sup>*</sup>More detailed contents in table can be found in the supplementary excel file</p></table-wrap-foot></table-wrap></p><p id="Par63">For drugs eliminated renally, research on the impact of inflammation on renal drug excretion remains limited. Critically ill patients experience complex pathophysiological changes that can either enhance or impair renal function [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR131">131</xref>&#8211;<xref ref-type="bibr" rid="CR135">135</xref>]. Our review primarily identified a negative correlation between inflammation and drug clearance, potentially due to the association between high inflammatory status and kidney injury [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR136">136</xref>&#8211;<xref ref-type="bibr" rid="CR138">138</xref>]. Inflammatory markers such as CRP, IL-6 and IL-18 have been linked to organ failure and could be indicators of acute kidney injury [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. In one study on end-stage renal disease patients, biomarkers including vWf, sVCAM&#8208;1 were found to be correlated with renal functions [<xref ref-type="bibr" rid="CR141">141</xref>]. In addition, one study found in critically ill patients, inflammation may lower the urine output [<xref ref-type="bibr" rid="CR19">19</xref>]. Conversely, some studies suggest that inflammation can elevate cardiac output and enhance glomerular filtration rate, potentially leading to increased drug clearance [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>], a phenomenon often observed in clinical practice as augmented renal clearance [<xref ref-type="bibr" rid="CR133">133</xref>]. This could also explain the exception noted in our review that the clearance of nadroparin and vancomycin increased with increasing inflammation.</p><p id="Par64">In critically ill patients, drug excretion is influenced by various factors, including augmented renal clearance (ARC), renal replacement therapies (RRT), and fluid overload. Inflammation may be a key factor underlying many of these changes. Inflammation can trigger ARC through mechanisms like vasodilation of afferent glomerular arterioles and increased cardiac output leading to increased renal blood flow [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. While CRRT can directly clear certain drugs, it may also remove inflammatory cytokines and promote the recovery of acute kidney injury (AKI), thus indirectly regulating drug excretion [<xref ref-type="bibr" rid="CR145">145</xref>]. Furthermore, fluid overload, often associated with inflammation-induced endothelial dysfunction and subsequent renal injury [<xref ref-type="bibr" rid="CR146">146</xref>], can significantly impair renal recovery [<xref ref-type="bibr" rid="CR147">147</xref>] and reduce drug clearance [<xref ref-type="bibr" rid="CR148">148</xref>]. Thus, volume status, renal function, and the use of renal replacement therapies all interact with the inflammatory state to affect drug excretion in critically ill patients.</p><p id="Par65">Take home messages for drug excretion: The influence of inflammation on the renally excreted drugs is complex and varies depending on the specific drug and patient population (e.g., adults vs. pediatrics). Clinicians should closely monitor renal function and drug concentrations in patients with inflammation to ensure optimal dosing and minimize the risk of adverse events.</p></sec><sec id="Sec11"><title>The impact of inflammation on ADME and clinical considerations</title><p id="Par66">Inflammation is a hallmark of critically ill disease and its level is measured in daily practice by different biomarkers. Our review summarizes the complex relationship between inflammatory biomarkers and PK parameters in critically ill patients. To unravel this complex relation we deduced it to the 4 different components of pharmacokinetics: absorption, distribution, metabolism and elimination. While previous research has suggested that inflammation can influence drug behavior in patients, most of these studies have primarily focused on specific CYP metabolism enzymes [<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>], on patients in non-ICU wards[<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>] or only on certain aspects of the process, such as drug penetration [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] or metabolism [<xref ref-type="bibr" rid="CR103">103</xref>]. The impact of inflammation on PK (i.e., downregulation of different enzymes and transporters) is well known, but the relationship with drug exposure in critically ill patients has not been fully appreciated. Our review highlights the multifaceted interplay between inflammation and pharmacokinetics (PK), often underestimated in previous pharmacokinetic studies. These complex interactions can lead to unpredictable drug exposures, particularly in critically ill patients under different inflammatory states (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>summary of inflammatory biomarkers on PK in critically ill patients. AUC: Area Under the Curve; C<sub>max</sub>: Maximum concentration; C<sub>unbound</sub>: Free drug concentration; C<sub>CSF</sub>: Cerebrospinal fluid concentration; C<sub>Peritoneal</sub>: Peritoneal drug concentration</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13054_2024_5150_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Complex relationship between inflammation and PK</title><p id="Par67">The relationship between the inflammation and drug exposure is complex. In this review, we observed that high levels of inflammation are generally associated with increased drug exposure in critically ill patients. However, findings are not consistent across all drugs and also differ across different patient groups, as our review found in the certain drugs like echinocandins, new triazoles (posaconazole and isavuconazole) and hydroxychloroquine (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>) did not show correlations between inflammatory biomarkers and drug exposure. One reason why the pharmacokinetics of certain drugs are not significantly influenced by inflammation may be that studies often assess only one inflammatory biomarker, such as CRP. Additionally, many of these medications, including echinocandins (e.g., anidulafungin, caspofungin) and newer triazoles (e.g., posaconazole, isavuconazole), are not primarily metabolized by CYP enzymes, making them less susceptible to changes caused by inflammation. In addition, for non-critically ill patients, there are differences in the impact of inflammation on PK (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>). These discrepancies highlight the diverse and complex effects of inflammation, influenced by patient condition and specific treatment. The effects of inflammation on some drugs were compared between ICU and non-ICU settings (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>). Overall, the impact of inflammation on pharmacokinetics appears to be consistent across both ICU and non-ICU setting. Take home messages for more general ICU drugs: Even in the non-ICU setting, inflammation can affect PK, and ICU physicians should be aware that in critically ill patients, inflammation is more severe and may have a more profound effect on PK. This makes extrapolation from non-ICU to ICU more difficult (Fig.&#160;<xref rid="Fig5" ref-type="fig">4</xref>).<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>drugs used in critically ill patients that are not influenced by the inflammation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug Class</th><th align="left" colspan="1" rowspan="1">Elimination pathway</th><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Time</th><th align="left" colspan="1" rowspan="1">Author</th><th align="left" colspan="1" rowspan="1">pt group</th><th align="left" colspan="1" rowspan="1">number</th><th align="left" colspan="1" rowspan="1">Effect</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antibacterial</td><td align="left" colspan="1" rowspan="1">Renal</td><td align="left" colspan="1" rowspan="1">Amikacin</td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">C. M. T. Sherwin</td><td align="left" colspan="1" rowspan="1">Children</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">CRP and platelet count were not associated with CL</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibacterial</td><td align="left" colspan="1" rowspan="1">Renal</td><td align="left" colspan="1" rowspan="1">Amikacin</td><td align="left" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">I. K. Delattre</td><td align="left" colspan="1" rowspan="1">Adults</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">CRP has no relationship with CL</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-fungal</td><td align="left" colspan="1" rowspan="1">slow chemical hydrolysi</td><td align="left" colspan="1" rowspan="1">Anidulafungin</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">P. Liu</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">PK did not differ between healthy and ICU patients</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-fungal</td><td align="left" colspan="1" rowspan="1">slow chemical hydrolysi</td><td align="left" colspan="1" rowspan="1">Caspofungin</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Agnieszka Borsuk-De Moor</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">No covariate (PCT) could explain the variability</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibacterial</td><td align="left" colspan="1" rowspan="1">Renal</td><td align="left" colspan="1" rowspan="1">Ceftriaxone</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Sonya Tang Girdwood</td><td align="left" colspan="1" rowspan="1">Children</td><td align="left" colspan="1" rowspan="1">195</td><td align="left" colspan="1" rowspan="1">CRP did not affect the CL of total and free ceftriaxone</td></tr><tr><td align="left" colspan="1" rowspan="1">DMARDs</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Hydroxychloroquine</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">A. K. Lyashchenko</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">421</td><td align="left" colspan="1" rowspan="1">Variability in systemic exposure could not be clearly explained by inflammatory status</td></tr><tr><td align="left" colspan="1" rowspan="1">DMARDs</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Hydroxychloroquine</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Catia Marzolini</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">No correlation between hydroxychloroquine concentrations and CRP</td></tr><tr><td align="left" colspan="1" rowspan="1">Analgesics</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Ketobemidone</td><td align="left" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">A. Al-Shurbaj</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">No relationship between CRP/WBC and CL</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-fungal</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Isavuconazole</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">L&#233;a Bolcato</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">No relationship between CRP and CL</td></tr><tr><td align="left" colspan="1" rowspan="1">Antibacterial</td><td align="left" colspan="1" rowspan="1">Renal</td><td align="left" colspan="1" rowspan="1">Linezolid</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">I. K. Minichmayr</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">No relationship between CRP and PK parameters</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-fungal</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Posaconazole</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Anne-Grete M&#228;rtson</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">No relationship between inflammatory biomarkers and CL</td></tr><tr><td align="left" colspan="1" rowspan="1">Anesthetic</td><td align="left" colspan="1" rowspan="1">Hepatic</td><td align="left" colspan="1" rowspan="1">Propofol</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">P. Smuszkiewicz</td><td align="left" colspan="1" rowspan="1">Adult</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">No relationship between CRP and CL</td></tr></tbody></table></table-wrap><fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Inflammation effect on pharmacodynamics</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13054_2024_5150_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Inflammation and pharmacodynamics</title><p id="Par68">The effects of inflammation on pharmacodynamics are multifaceted (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). On the one hand, inflammation can indirectly influence drug efficacy and safety by altering pharmacokinetics, leading to supra- or sub-therapeutic drug concentrations. On the other hand, inflammation can downregulate certain drug receptors, such as calcium channel blockers, &#946;-adrenoreceptors, and potassium channel antagonists, reducing their efficacy despite increased plasma drug concentrations [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR158">158</xref>]. Furthermore, the interplay between inflammation&#8217;s direct and indirect effects on PD can further complicate the clinical picture.</p><p id="Par69">For the PK-related influence on PD, piperacillin and voriconazole demonstrate how high inflammation can lead to elevated drug concentrations and increased toxicity [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. For the inflammation effect on PD, in midazolam, increased drug exposure occurs during inflammation; however, reducing the dosage is not recommended [<xref ref-type="bibr" rid="CR159">159</xref>]. And in the case of prasugrel, the reduced antiplatelet effect may be attributed not only to decreased levels of its active metabolite but also to inflammation-induced increases in platelet reactivity.</p><p id="Par70">Despite some evidence indicating that inflammation can lead to toxicity in both ICU and non-ICU settings, research exploring the direct relationships between inflammatory biomarkers and PD outcomes remains limited. Now sometimes this is not a problem in daily practice, as the pharmacodynamic effect can be closely monitored, for example vasopressors or sedatives, or easily measured, for example heparin and vancomycin, but for other drugs this is not, including certain antibiotics, immunomodulators and antiplatelets, both essential drugs for the disease they are prescribed for.</p><p id="Par71">Take-home message: Clinicians should carefully consider dosing adjustments for patients with high inflammatory states, balancing the potential risks and benefits of medication administration under these complex conditions.</p></sec><sec id="Sec14"><title>Promising biomarkers</title><p id="Par72">Inflammatory biomarkers hold promise for guiding drug dosing in critically ill patients. In our review, CRP appears to be the biomarker most consistently associated with alterations in pharmacokinetic parameters, particularly those related to metabolism. This observation may be attributable to the prevalent monitoring of CRP as an inflammatory biomarker in critically ill patients compared with other inflammatory biomarkers (IL-6, IL-8, etc.). At the same time, CRP is a rather non-specific inflammatory biomarkers There are other promising inflammatory, including more specific, biomarkers, of interest (Supplementary file <xref rid="MOESM2" ref-type="media">4</xref>). An ideal biomarker should be both specific and easily available. Unfortunately, we need more research for this, and CRP will until then by the best surrogate. Based on the results of our review, we propose a targeted approach to refine future pharmacokinetic clinical trial designs (shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">5</xref>). By tailoring trial protocols to specific therapeutic agents (e.g., anticoagulants, anti-infectives, and analgesics), we aim to determine the most relevant pharmacokinetic parameters (such as peak concentration, free drug concentration, target organ tissue concentration, steady-state concentration, etc.). Incorporating more specific inflammatory biomarkers will better elucidate PK variability among critically ill patients, potentially leading to improved clinical outcomes. And in future PK studies in critically ill patients, longer follow-up period is needed since the inflammation effects on PK parameters may differs in different patterns of inflammation (pro- or anti-inflammatory, early or late) which already found in certain drugs like vancomycin [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. AI could be a valuable tool for precision dosing, given its ability to manage large datasets and enhance biomarker identification [<xref ref-type="bibr" rid="CR162">162</xref>]. This is especially beneficial for critically ill patients experiencing dynamic inflammatory conditions and requiring continuous monitoring. Take home messages for promising biomarkers: Inflammatory biomarkers that reflect organ functions (especially for liver and renal functions) can be invaluable in improving precision dosing in critically ill patients, ensuring both efficacy and safety in treatment protocols.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Suggestions for future ICU pharmacokinetic clinical trials. ESR: Erythrocyte Sedimentation Rate; FABP: Fatty acid-binding protein; WBC: white blood cell. Cmax: Maximum concentration; Tmax: Time to maximum concentration; Ctarget: Target concentration; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; IL-1: Interleukin-1; IL-6: Interleukin-6; WBC: White Blood Cell Count; TNF-&#945;: Tumor Necrosis Factor-alpha</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13054_2024_5150_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Limitations</title><p id="Par73">Our review has several limitations. The main limitation is that due to limited literature and evidence, this review is limited to pharmacokinetics and does not consider pharmacodynamics. Next to this, we had to reduce real-life complexity by using a classic pharmacokinetic approach (ADME), but effects on pharmacokinetics will never be limited to only one of these parameters. Third, the number of drugs found in literature is limited, especially regarding all 4 pharmacokinetic parameters. Fourth, the search was restricted to English-language publications, potentially excluding relevant research in other languages. Fifth, by focusing on studies incorporating inflammatory biomarkers, we may have missed studies that qualitatively explored the impact of inflammation on PK, though they lacked quantitative measures. Sixth, the evidence linking inflammatory markers to PK parameters in critically ill patients remains sparse and inconsistent, limiting the generalizability of our findings. Seventh, attributing PK changes solely to inflammation in the complex ICU environment is challenging due to confounding factors such as fluid therapy, CRRT, disease severity, and renal function, which often correlate with inflammation. Eighth, data on drug interactions and comedication, crucial in the polypharmacy setting of most ICUs, were often missing from included studies. Ninth, while the impact of inflammation on drug pharmacokinetics may exhibit similarities in non-ICU settings, direct extrapolation between these settings should be avoided due to the significant differences in the severity and nature of inflammation. Finally, the lack of studies investigating the relationship between inflammation and pharmacodynamics in critically ill patients hinders our ability to provide precise dosing recommendations for clinicians. Future research should address these limitations to improve our understanding of the complex interplay between inflammation and drug disposition in critically ill patients.</p></sec></sec><sec id="Sec16"><title>Conclusion</title><p id="Par74">Our review underscores the importance of inflammation as a key factor influencing the complex drug PK behavior in the critically ill patients. To optimize treatment efficacy, one should consider each patient&#8217;s specific inflammatory profile. Furthermore, future PK-related clinical trials conducted in critically ill patients should consider the heterogeneity of patients&#8217; inflammatory status. This involves monitoring inflammatory biomarkers in critically ill patients, which will provide a clearer understanding of the interplay between inflammation, organ function, and PK behavior across diverse patient groups.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13054_2024_5150_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Additional file 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13054_2024_5150_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Additional file 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13054_2024_5150_MOESM3_ESM.xlsx" position="float" orientation="portrait"><caption><p>Additional file 3.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAG</term><def><p id="Par6">Alpha-1-acid glycoprotein</p></def></def-item><def-item><term>ADME</term><def><p id="Par7">Absorption, distribution, metabolism, and excretion</p></def></def-item><def-item><term>AKI</term><def><p id="Par8">Acute kidney injury</p></def></def-item><def-item><term>ARC</term><def><p id="Par9">Augmented renal clearance</p></def></def-item><def-item><term>ARDS</term><def><p id="Par10">Acute respiratory distress syndrome</p></def></def-item><def-item><term>AUC</term><def><p id="Par11">Area under the curve</p></def></def-item><def-item><term>BBB</term><def><p id="Par12">Blood&#8211;brain barrier</p></def></def-item><def-item><term>BCRP</term><def><p id="Par13">Breast cancer resistance protein</p></def></def-item><def-item><term>CL</term><def><p id="Par14">Clearance</p></def></def-item><def-item><term>Cmax</term><def><p id="Par15">Maximum concentration</p></def></def-item><def-item><term>CRP</term><def><p id="Par16">C-reactive protein</p></def></def-item><def-item><term>CSF</term><def><p id="Par17">Cerebrospinal fluid</p></def></def-item><def-item><term>Ctrough</term><def><p id="Par18">Trough concentration</p></def></def-item><def-item><term>CYP</term><def><p id="Par19">Cytochrome P450</p></def></def-item><def-item><term>EMBASE</term><def><p id="Par20">Excerpta medica database</p></def></def-item><def-item><term>ESR</term><def><p id="Par21">Erythrocyte sedimentation rate</p></def></def-item><def-item><term>ICU</term><def><p id="Par22">Intensive care unit</p></def></def-item><def-item><term>IL-6</term><def><p id="Par23">Interleukin-6</p></def></def-item><def-item><term>MIC</term><def><p id="Par24">Minimum inhibitory concentration</p></def></def-item><def-item><term>MODS</term><def><p id="Par25">Multiple organ dysfunction syndrome</p></def></def-item><def-item><term>MRP2</term><def><p id="Par26">Multidrug resistance-associated protein 2</p></def></def-item><def-item><term>PCT</term><def><p id="Par27">Procalcitonin</p></def></def-item><def-item><term>PD</term><def><p id="Par28">Pharmacodynamics</p></def></def-item><def-item><term>P-gp</term><def><p id="Par29">P-glycoprotein</p></def></def-item><def-item><term>PK</term><def><p id="Par30">Pharmacokinetics</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par31">Preferred reporting items for systematic reviews and meta-analyses</p></def></def-item><def-item><term>RRT</term><def><p id="Par32">Renal replacement therapy</p></def></def-item><def-item><term>SIRS</term><def><p id="Par33">Systemic inflammatory response syndrome</p></def></def-item><def-item><term>TNF-&#945;</term><def><p id="Par34">Tumor necrosis factor-alpha</p></def></def-item><def-item><term>tmax</term><def><p id="Par35">Time to reach peak concentration</p></def></def-item><def-item><term>UGT</term><def><p id="Par36">UDP-glucuronosyltransferase</p></def></def-item><def-item><term>Vd</term><def><p id="Par37">Volume of distribution</p></def></def-item><def-item><term>WBC</term><def><p id="Par38">White blood cell</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors wish to thank Wichor Bramer from the Erasmus MC Medical Library for developing and updating the search strategies.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.L and J.Z did the systematic search. L.L wrote the main manuscript text. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval and consent to participate</title><p id="Par75">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par76">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morales Castro</surname><given-names>D</given-names></name><name name-style="western"><surname>Dresser</surname><given-names>L</given-names></name><name name-style="western"><surname>Granton</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetic alterations associated with critical illness</article-title><source>Clin Pharmacokinet</source><year>2023</year><volume>62</volume><issue>2</issue><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s40262-023-01213-x</pub-id><pub-id pub-id-type="pmid">36732476</pub-id><pub-id pub-id-type="pmcid">PMC9894673</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2):209&#8211;20.<pub-id pub-id-type="pmid">36732476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01213-x</pub-id><pub-id pub-id-type="pmcid">PMC9894673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Martinez CPC, Salcedo SSS, Lee FAR, Salcedo JAM, Hernandez CJC, Orrego MYM, Barrios RAL, Fontecha ERA: Pharmacokinetics in Critically Ill Patients, What Changes? 2023.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoller</surname><given-names>M</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B</given-names></name><name name-style="western"><surname>Hornuss</surname><given-names>C</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>C</given-names></name><name name-style="western"><surname>D&#246;bbeler</surname><given-names>G</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>D</given-names></name><name name-style="western"><surname>Holdt</surname><given-names>LM</given-names></name><name name-style="western"><surname>Bruegel</surname><given-names>M</given-names></name><name name-style="western"><surname>Weig</surname><given-names>T</given-names></name><name name-style="western"><surname>Grabein</surname><given-names>B</given-names></name><etal/></person-group><article-title>Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study</article-title><source>Crit Care</source><year>2014</year><volume>18</volume><issue>4</issue><fpage>R148</fpage><pub-id pub-id-type="doi">10.1186/cc13984</pub-id><pub-id pub-id-type="pmid">25011656</pub-id><pub-id pub-id-type="pmcid">PMC4227093</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zoller M, Maier B, Hornuss C, Neugebauer C, D&#246;bbeler G, Nagel D, Holdt LM, Bruegel M, Weig T, Grabein B, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18(4):R148.<pub-id pub-id-type="pmid">25011656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc13984</pub-id><pub-id pub-id-type="pmcid">PMC4227093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brink</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Richards</surname><given-names>GA</given-names></name><name name-style="western"><surname>Schillack</surname><given-names>V</given-names></name><name name-style="western"><surname>Kiem</surname><given-names>S</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis</article-title><source>Int J Antimicrob Agents</source><year>2009</year><volume>33</volume><issue>5</issue><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2008.10.005</pub-id><pub-id pub-id-type="pmid">19091521</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 2009;33(5):432&#8211;6.<pub-id pub-id-type="pmid">19091521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2008.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinnollareddy</surname><given-names>M</given-names></name><name name-style="western"><surname>Peake</surname><given-names>SL</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review</article-title><source>Int J Antimicrob Agents</source><year>2012</year><volume>39</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2011.07.013</pub-id><pub-id pub-id-type="pmid">21925845</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents. 2012;39(1):1&#8211;10.<pub-id pub-id-type="pmid">21925845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2011.07.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewoldt</surname><given-names>TMJ</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A</given-names></name><name name-style="western"><surname>Rietdijk</surname><given-names>WJR</given-names></name><name name-style="western"><surname>Muller</surname><given-names>AE</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>BCM</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>NGM</given-names></name><name name-style="western"><surname>Purmer</surname><given-names>IM</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>P</given-names></name><name name-style="western"><surname>Wils</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Haringman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial</article-title><source>Intensive Care Med</source><year>2022</year><volume>48</volume><issue>12</issue><fpage>1760</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1007/s00134-022-06921-9</pub-id><pub-id pub-id-type="pmid">36350354</pub-id><pub-id pub-id-type="pmcid">PMC9645317</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, Purmer IM, van Vliet P, Wils EJ, Haringman J, et al. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med. 2022;48(12):1760&#8211;71.<pub-id pub-id-type="pmid">36350354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-022-06921-9</pub-id><pub-id pub-id-type="pmcid">PMC9645317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>RM</given-names></name><name name-style="western"><surname>Roggeveen</surname><given-names>LF</given-names></name><name name-style="western"><surname>Fleuren</surname><given-names>LM</given-names></name><name name-style="western"><surname>Thoral</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>van der Voort</surname><given-names>PHJ</given-names></name><name name-style="western"><surname>Girbes</surname><given-names>ARJ</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>RAA</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>PWG</given-names></name></person-group><article-title>External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><pub-id pub-id-type="doi">10.1128/AAC.02543-18</pub-id><pub-id pub-id-type="pmid">30833424</pub-id><pub-id pub-id-type="pmcid">PMC6496102</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Guo T, van Hest RM, Roggeveen LF, Fleuren LM, Thoral PJ, Bosman RJ, van der Voort PHJ, Girbes ARJ, Mathot RAA, Elbers PWG. External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients. Antimicrob Agents Chemother. 2019. 10.1128/AAC.02543-18.<pub-id pub-id-type="pmid">30833424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02543-18</pub-id><pub-id pub-id-type="pmcid">PMC6496102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>SDT</given-names></name><name name-style="western"><surname>Ewoldt</surname><given-names>TMJ</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>NGM</given-names></name><name name-style="western"><surname>Muller</surname><given-names>AE</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>BCM</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></name></person-group><article-title>Meropenem model-informed precision dosing in the treatment of critically Ill patients: Can we use it?</article-title><source>Antibiotics (Basel)</source><year>2023</year><volume>12</volume><issue>2</issue><fpage>383</fpage><pub-id pub-id-type="doi">10.3390/antibiotics12020383</pub-id><pub-id pub-id-type="pmid">36830294</pub-id><pub-id pub-id-type="pmcid">PMC9951903</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Li L, Sassen SDT, Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, de Winter BCM, Endeman H, Koch BCP. Meropenem model-informed precision dosing in the treatment of critically Ill patients: Can we use it? Antibiotics (Basel). 2023;12(2):383.<pub-id pub-id-type="pmid">36830294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics12020383</pub-id><pub-id pub-id-type="pmcid">PMC9951903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lk</surname><given-names>A</given-names></name></person-group><article-title>Inflammation in focus: the beginning and the end</article-title><source>Pathol Oncol Res</source><year>2021</year><volume>27</volume><fpage>1610136</fpage><pub-id pub-id-type="pmid">35058736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2021.1610136</pub-id><pub-id pub-id-type="pmcid">PMC8763665</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lk A. Inflammation in focus: the beginning and the end. Pathol Oncol Res. 2021;27:1610136.<pub-id pub-id-type="pmid">35058736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2021.1610136</pub-id><pub-id pub-id-type="pmcid">PMC8763665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name></person-group><article-title>Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><issue>7 Suppl</issue><fpage>S99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1097/00003246-200107001-00032</pub-id><pub-id pub-id-type="pmid">11445742</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med. 2001;29(7 Suppl):S99-106.<pub-id pub-id-type="pmid">11445742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-200107001-00032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Teshima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Otsubo</surname><given-names>H</given-names></name><name name-style="western"><surname>Shimazui</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>TA</given-names></name><name name-style="western"><surname>Takasu</surname><given-names>O</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>J</given-names></name><name name-style="western"><surname>Nabeta</surname><given-names>M</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Risk prediction of biomarkers for early multiple organ dysfunction in critically ill patients</article-title><source>BMC Emerg Med</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>132</fpage><pub-id pub-id-type="doi">10.1186/s12873-021-00534-z</pub-id><pub-id pub-id-type="pmid">34749673</pub-id><pub-id pub-id-type="pmcid">PMC8573766</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ishikawa S, Teshima Y, Otsubo H, Shimazui T, Nakada TA, Takasu O, Matsuda K, Sasaki J, Nabeta M, Moriguchi T, et al. Risk prediction of biomarkers for early multiple organ dysfunction in critically ill patients. BMC Emerg Med. 2021;21(1):132.<pub-id pub-id-type="pmid">34749673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12873-021-00534-z</pub-id><pub-id pub-id-type="pmcid">PMC8573766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jabaudon</surname><given-names>M</given-names></name><name name-style="western"><surname>Blondonnet</surname><given-names>R</given-names></name><name name-style="western"><surname>Ware</surname><given-names>LB</given-names></name></person-group><article-title>Biomarkers in acute respiratory distress syndrome</article-title><source>Curr Opin Crit Care</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/MCC.0000000000000786</pub-id><pub-id pub-id-type="pmid">33278123</pub-id><pub-id pub-id-type="pmcid">PMC7774234</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Jabaudon M, Blondonnet R, Ware LB. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care. 2021;27(1):46&#8211;54.<pub-id pub-id-type="pmid">33278123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCC.0000000000000786</pub-id><pub-id pub-id-type="pmcid">PMC7774234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummel</surname><given-names>NE</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CG</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>JB</given-names></name><name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Orun</surname><given-names>OM</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R</given-names></name><name name-style="western"><surname>Ware</surname><given-names>LB</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>GR</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>FE</given-names></name><etal/></person-group><article-title>Systemic inflammation and delirium during critical illness</article-title><source>Intensive Care Med</source><year>2024</year><volume>50</volume><issue>5</issue><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s00134-024-07388-6</pub-id><pub-id pub-id-type="pmid">38647548</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Brummel NE, Hughes CG, McNeil JB, Pandharipande PP, Thompson JL, Orun OM, Raman R, Ware LB, Bernard GR, Harrison FE, et al. Systemic inflammation and delirium during critical illness. Intensive Care Med. 2024;50(5):687&#8211;96.<pub-id pub-id-type="pmid">38647548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-024-07388-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hall</surname><given-names>RI</given-names></name></person-group><article-title>Drug absorption, distribution, metabolism and excretion considerations in critically ill adults</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2013</year><volume>9</volume><issue>9</issue><fpage>1067</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1517/17425255.2013.799137</pub-id><pub-id pub-id-type="pmid">23682923</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9(9):1067&#8211;84.<pub-id pub-id-type="pmid">23682923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2013.799137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos-Borges</surname><given-names>KT</given-names></name><name name-style="western"><surname>Henz</surname><given-names>P</given-names></name></person-group><article-title>Ara&#250;jo BVd: the influence of sepsis on antimicrobials tissue penetration: the use of microdialysis technique to access free drug distribution</article-title><source>Braz J Pharm Sci</source><year>2023</year><volume>59</volume><fpage>e22982</fpage><pub-id pub-id-type="doi">10.1590/s2175-97902023e22982</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Santos-Borges KT, Henz P. Ara&#250;jo BVd: the influence of sepsis on antimicrobials tissue penetration: the use of microdialysis technique to access free drug distribution. Braz J Pharm Sci. 2023;59: e22982.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewoldt</surname><given-names>TM</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Smeets</surname><given-names>TJL</given-names></name><name name-style="western"><surname>Gommers</surname><given-names>D</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name></person-group><article-title>The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2022</year><volume>18</volume><issue>6</issue><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/17425255.2022.2106215</pub-id><pub-id pub-id-type="pmid">35912845</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ewoldt TM, Abdulla A, Hunfeld N, Li L, Smeets TJL, Gommers D, Koch BCP, Endeman H. The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review. Expert Opin Drug Metab Toxicol. 2022;18(6):413&#8211;21.<pub-id pub-id-type="pmid">35912845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2022.2106215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poloyac</surname><given-names>SM</given-names></name></person-group><article-title>Altered drug metabolism in critically ill children: a significant source of adverse effects?</article-title><source>Pediatr Crit Care Med</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>118</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1097/PCC.0b013e318202f5a6</pub-id><pub-id pub-id-type="pmid">22222658</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Poloyac SM. Altered drug metabolism in critically ill children: a significant source of adverse effects? Pediatr Crit Care Med. 2012;13(1):118&#8211;9.<pub-id pub-id-type="pmid">22222658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PCC.0b013e318202f5a6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Aulin</surname><given-names>LBS</given-names></name><name name-style="western"><surname>Manson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Krekels</surname><given-names>EHJ</given-names></name><name name-style="western"><surname>van Hasselt</surname><given-names>JGC</given-names></name></person-group><article-title>Unraveling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2023</year><volume>48</volume><issue>6</issue><fpage>623</fpage><pub-id pub-id-type="doi">10.1007/s13318-023-00852-6</pub-id><pub-id pub-id-type="pmid">37715056</pub-id><pub-id pub-id-type="pmcid">PMC10624742</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu F, Aulin LBS, Manson ML, Krekels EHJ, van Hasselt JGC. Unraveling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism. Eur J Drug Metab Pharmacokinet. 2023;48(6):623.<pub-id pub-id-type="pmid">37715056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13318-023-00852-6</pub-id><pub-id pub-id-type="pmcid">PMC10624742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimazui</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>TA</given-names></name><name name-style="western"><surname>Tateishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Aizimu</surname><given-names>T</given-names></name><name name-style="western"><surname>Oda</surname><given-names>S</given-names></name></person-group><article-title>Association between serum levels of interleukin-6 on ICU admission and subsequent outcomes in critically ill patients with acute kidney injury</article-title><source>BMC Nephrol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s12882-019-1265-6</pub-id><pub-id pub-id-type="pmid">30823904</pub-id><pub-id pub-id-type="pmcid">PMC6397495</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Shimazui T, Nakada TA, Tateishi Y, Oshima T, Aizimu T, Oda S. Association between serum levels of interleukin-6 on ICU admission and subsequent outcomes in critically ill patients with acute kidney injury. BMC Nephrol. 2019;20(1):74.<pub-id pub-id-type="pmid">30823904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-019-1265-6</pub-id><pub-id pub-id-type="pmcid">PMC6397495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Combined effect of CYP2C19 genetic polymorphisms and C-reactive protein on voriconazole exposure and dosing in immunocompromised children</article-title><source>Front Pediatr</source><year>2022</year><volume>10</volume><fpage>846411</fpage><pub-id pub-id-type="doi">10.3389/fped.2022.846411</pub-id><pub-id pub-id-type="pmid">35386257</pub-id><pub-id pub-id-type="pmcid">PMC8978631</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen J, Wu Y, He Y, Feng X, Ren Y, Liu S. Combined effect of CYP2C19 genetic polymorphisms and C-reactive protein on voriconazole exposure and dosing in immunocompromised children. Front Pediatr. 2022;10: 846411.<pub-id pub-id-type="pmid">35386257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2022.846411</pub-id><pub-id pub-id-type="pmcid">PMC8978631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XP</given-names></name><name name-style="western"><surname>Dong</surname><given-names>LL</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zou</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hu</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name></person-group><article-title>Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance</article-title><source>J Clin Pharm Ther</source><year>2022</year><volume>47</volume><issue>4</issue><fpage>483</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1111/jcpt.13569</pub-id><pub-id pub-id-type="pmid">34779003</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ling J, Yang XP, Dong LL, Jiang Y, Zou SL, Hu N, Chen R. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance. J Clin Pharm Ther. 2022;47(4):483&#8211;92.<pub-id pub-id-type="pmid">34779003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.13569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>P</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Population pharmacokinetics and dosing regimen optimization of linezolid in cerebrospinal fluid and plasma of post-operative neurosurgical patients</article-title><source>J Pharm Sci</source><year>2023</year><volume>112</volume><issue>3</issue><fpage>884</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.12.016</pub-id><pub-id pub-id-type="pmid">36566928</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Li S, Wang Y, Dong H, Zhu Y, Cao P, Meng L, Wang Y. Population pharmacokinetics and dosing regimen optimization of linezolid in cerebrospinal fluid and plasma of post-operative neurosurgical patients. J Pharm Sci. 2023;112(3):884&#8211;92.<pub-id pub-id-type="pmid">36566928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2022.12.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyoshima</surname><given-names>J</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaibara</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>Y</given-names></name><name name-style="western"><surname>Izutsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></name></person-group><article-title>Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis</article-title><source>Br J Clin Pharmacol</source><year>2021</year><volume>87</volume><issue>4</issue><fpage>2014</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1111/bcp.14605</pub-id><pub-id pub-id-type="pmid">33068028</pub-id><pub-id pub-id-type="pmcid">PMC8056739</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2021;87(4):2014&#8211;22.<pub-id pub-id-type="pmid">33068028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14605</pub-id><pub-id pub-id-type="pmcid">PMC8056739</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krogh-Madsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Bender</surname><given-names>B</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Honor&#233;</surname><given-names>PH</given-names></name></person-group><article-title>Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia</article-title><source>Cancer Chemother Pharmacol</source><year>2012</year><volume>69</volume><issue>5</issue><fpage>1155</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1007/s00280-011-1800-z</pub-id><pub-id pub-id-type="pmid">22212298</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honor&#233; PH. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol. 2012;69(5):1155&#8211;63.<pub-id pub-id-type="pmid">22212298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-011-1800-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonate</surname><given-names>PL</given-names></name><name name-style="western"><surname>Craig</surname><given-names>A</given-names></name><name name-style="western"><surname>Gaynon</surname><given-names>P</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>V</given-names></name><name name-style="western"><surname>Jeha</surname><given-names>S</given-names></name><name name-style="western"><surname>Kadota</surname><given-names>R</given-names></name><name name-style="western"><surname>Lam</surname><given-names>GN</given-names></name><name name-style="western"><surname>Plunkett</surname><given-names>W</given-names></name><name name-style="western"><surname>Razzouk</surname><given-names>B</given-names></name><name name-style="western"><surname>Rytting</surname><given-names>M</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia</article-title><source>J Clin Pharmacol</source><year>2004</year><volume>44</volume><issue>11</issue><fpage>1309</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1177/0091270004269236</pub-id><pub-id pub-id-type="pmid">15496649</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004;44(11):1309&#8211;22.<pub-id pub-id-type="pmid">15496649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270004269236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidli</surname><given-names>H</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Capdeville</surname><given-names>R</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>M</given-names></name><name name-style="western"><surname>Gathmann</surname><given-names>I</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>AE</given-names></name><name name-style="western"><surname>Racine-Poon</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>60</volume><issue>1</issue><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02372.x</pub-id><pub-id pub-id-type="pmid">15963092</pub-id><pub-id pub-id-type="pmcid">PMC1884912</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005;60(1):35&#8211;44.<pub-id pub-id-type="pmid">15963092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02372.x</pub-id><pub-id pub-id-type="pmcid">PMC1884912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Admiraal</surname><given-names>R</given-names></name><name name-style="western"><surname>van Kesteren</surname><given-names>C</given-names></name><name name-style="western"><surname>Jol-van der Zijde</surname><given-names>CM</given-names></name><name name-style="western"><surname>van Tol</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bartelink</surname><given-names>IH</given-names></name><name name-style="western"><surname>Bredius</surname><given-names>RG</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>CA</given-names></name></person-group><article-title>Population pharmacokinetic modeling of thymoglobulin<sup>&#174;</sup> in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing</article-title><source>Clin Pharm</source><year>2015</year><volume>54</volume><fpage>435</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/s40262-014-0214-6</pub-id><pub-id pub-id-type="pmid">25466602</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA. Population pharmacokinetic modeling of thymoglobulin<sup>&#174;</sup> in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharm. 2015;54:435&#8211;46.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-014-0214-6</pub-id><pub-id pub-id-type="pmid">25466602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>T</given-names></name><name name-style="western"><surname>Colman</surname><given-names>R</given-names></name><name name-style="western"><surname>Hyams</surname><given-names>J</given-names></name><name name-style="western"><surname>Noe</surname><given-names>JD</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>B</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>YT</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>K</given-names></name><name name-style="western"><surname>Punt</surname><given-names>N</given-names></name><etal/></person-group><article-title>Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn&#8217;s disease</article-title><source>Clin Pharmacol Ther</source><year>2021</year><volume>109</volume><issue>6</issue><fpage>1639</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1002/cpt.2148</pub-id><pub-id pub-id-type="pmid">33354765</pub-id><pub-id pub-id-type="pmcid">PMC8159860</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, Tsai YT, Dong M, Jackson K, Punt N, et al. Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn&#8217;s disease. Clin Pharmacol Ther. 2021;109(6):1639&#8211;47.<pub-id pub-id-type="pmid">33354765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2148</pub-id><pub-id pub-id-type="pmcid">PMC8159860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wade</surname><given-names>JR</given-names></name><name name-style="western"><surname>Parker</surname><given-names>G</given-names></name><name name-style="western"><surname>Kosutic</surname><given-names>G</given-names></name><name name-style="western"><surname>Feagen</surname><given-names>BG</given-names></name><name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Laveille</surname><given-names>C</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>R</given-names></name></person-group><article-title>Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn&#8217;s disease</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><issue>8</issue><fpage>866</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1002/jcph.491</pub-id><pub-id pub-id-type="pmid">25735646</pub-id><pub-id pub-id-type="pmcid">PMC6680228</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn&#8217;s disease. J Clin Pharmacol. 2015;55(8):866&#8211;74.<pub-id pub-id-type="pmid">25735646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.491</pub-id><pub-id pub-id-type="pmcid">PMC6680228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Teramoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Jaber</surname><given-names>MM</given-names></name><name name-style="western"><surname>Tamaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Ikegame</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaida</surname><given-names>K</given-names></name></person-group><article-title>Population pharmacokinetics of total rabbit anti-thymocyte globulin in non-obese adult patients undergoing hematopoietic cell transplantation for hematologic malignancy</article-title><source>Clin Pharmacokinet</source><year>2023</year><volume>62</volume><issue>8</issue><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1007/s40262-023-01252-4</pub-id><pub-id pub-id-type="pmid">37284975</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Takahashi T, Teramoto M, Matsumoto K, Jaber MM, Tamaki H, Ikegame K, Yoshihara S, Kaida K. Population pharmacokinetics of total rabbit anti-thymocyte globulin in non-obese adult patients undergoing hematopoietic cell transplantation for hematologic malignancy. Clin Pharmacokinet. 2023;62(8):1081&#8211;91.<pub-id pub-id-type="pmid">37284975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01252-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastida</surname><given-names>C</given-names></name><name name-style="western"><surname>Ruiz-Esquide</surname><given-names>V</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>M</given-names></name><name name-style="western"><surname>de Vries Schultink</surname><given-names>AH</given-names></name><name name-style="western"><surname>Yag&#252;e</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanmart&#237;</surname><given-names>R</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D</given-names></name></person-group><article-title>Fixed dosing of intravenous tocilizumab in rheumatoid arthritis Results from a population pharmacokinetic analysis</article-title><source>Br J Clin Pharmacol</source><year>2018</year><volume>84</volume><issue>4</issue><fpage>716</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/bcp.13500</pub-id><pub-id pub-id-type="pmid">29314183</pub-id><pub-id pub-id-type="pmcid">PMC5867112</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AH, Yag&#252;e J, Sanmart&#237; R, Huitema AD, Soy D. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018;84(4):716&#8211;25.<pub-id pub-id-type="pmid">29314183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13500</pub-id><pub-id pub-id-type="pmcid">PMC5867112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>M</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name></person-group><article-title>The cytokine release syndrome and/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug-disease interaction under different clinical conditions</article-title><source>Clin Pharmacokinet</source><year>2022</year><volume>61</volume><issue>11</issue><fpage>1519</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01173-8</pub-id><pub-id pub-id-type="pmid">36059001</pub-id><pub-id pub-id-type="pmcid">PMC9441320</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gatti M, Pea F. The cytokine release syndrome and/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug-disease interaction under different clinical conditions. Clin Pharmacokinet. 2022;61(11):1519&#8211;44.<pub-id pub-id-type="pmid">36059001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-022-01173-8</pub-id><pub-id pub-id-type="pmcid">PMC9441320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanke-Labesque</surname><given-names>F</given-names></name><name name-style="western"><surname>Gautier-Veyret</surname><given-names>E</given-names></name><name name-style="western"><surname>Chhun</surname><given-names>S</given-names></name><name name-style="western"><surname>Guilhaumou</surname><given-names>R</given-names></name></person-group><article-title>French society of P, therapeutics: inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment</article-title><source>Pharmacol Ther</source><year>2020</year><volume>215</volume><fpage>107627</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107627</pub-id><pub-id pub-id-type="pmid">32659304</pub-id><pub-id pub-id-type="pmcid">PMC7351663</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. French society of P, therapeutics: inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215: 107627.<pub-id pub-id-type="pmid">32659304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2020.107627</pub-id><pub-id pub-id-type="pmcid">PMC7351663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Ghiaty</surname><given-names>MA</given-names></name><name name-style="western"><surname>Shoieb</surname><given-names>SM</given-names></name><name name-style="western"><surname>El-Kadi</surname><given-names>AOS</given-names></name></person-group><article-title>Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms</article-title><source>Med Hypotheses</source><year>2020</year><volume>144</volume><fpage>110033</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2020.110033</pub-id><pub-id pub-id-type="pmid">32758877</pub-id><pub-id pub-id-type="pmcid">PMC7318945</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses. 2020;144: 110033.<pub-id pub-id-type="pmid">32758877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2020.110033</pub-id><pub-id pub-id-type="pmcid">PMC7318945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunvald</surname><given-names>AD</given-names></name><name name-style="western"><surname>J&#228;rvinen</surname><given-names>E</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>C</given-names></name><name name-style="western"><surname>Stage</surname><given-names>TB</given-names></name></person-group><article-title>Clinical and molecular perspectives on inflammation-mediated regulation of drug metabolism and transport</article-title><source>Clin Pharmacol Ther</source><year>2022</year><volume>112</volume><issue>2</issue><fpage>277</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/cpt.2432</pub-id><pub-id pub-id-type="pmid">34605009</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dunvald AD, J&#228;rvinen E, Mortensen C, Stage TB. Clinical and molecular perspectives on inflammation-mediated regulation of drug metabolism and transport. Clin Pharmacol Ther. 2022;112(2):277&#8211;90.<pub-id pub-id-type="pmid">34605009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CJ</given-names></name></person-group><article-title>The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders</article-title><source>J Food Drug Anal</source><year>2019</year><volume>27</volume><issue>1</issue><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jfda.2018.11.005</pub-id><pub-id pub-id-type="pmid">30648594</pub-id><pub-id pub-id-type="pmcid">PMC9298621</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wu KC, Lin CJ. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders. J Food Drug Anal. 2019;27(1):48&#8211;59.<pub-id pub-id-type="pmid">30648594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jfda.2018.11.005</pub-id><pub-id pub-id-type="pmcid">PMC9298621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coutant</surname><given-names>DE</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance</article-title><source>J Clin Pharmacol</source><year>2018</year><volume>58</volume><issue>7</issue><fpage>849</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1002/jcph.1093</pub-id><pub-id pub-id-type="pmid">29505093</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Coutant DE, Hall SD. Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2018;58(7):849&#8211;63.<pub-id pub-id-type="pmid">29505093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierce</surname><given-names>JD</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>S</given-names></name><name name-style="western"><surname>White</surname><given-names>N</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>RL</given-names></name></person-group><article-title>Biomarkers: an important clinical assessment tool</article-title><source>Am J Nurs</source><year>2012</year><volume>112</volume><issue>9</issue><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1097/01.NAJ.0000418926.83718.28</pub-id><pub-id pub-id-type="pmid">22932054</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Pierce JD, McCabe S, White N, Clancy RL. Biomarkers: an important clinical assessment tool. Am J Nurs. 2012;112(9):52&#8211;8.<pub-id pub-id-type="pmid">22932054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.NAJ.0000418926.83718.28</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bogossian</surname><given-names>E</given-names></name><name name-style="western"><surname>Menozzi</surname><given-names>M</given-names></name></person-group><article-title>The future of biomarkers</article-title><source>Crit Care Clin</source><year>2020</year><volume>36</volume><issue>1</issue><fpage>177</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2019.08.014</pub-id><pub-id pub-id-type="pmid">31733679</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Vincent JL, Bogossian E, Menozzi M. The future of biomarkers. Crit Care Clin. 2020;36(1):177&#8211;87.<pub-id pub-id-type="pmid">31733679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccc.2019.08.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dao</surname><given-names>L</given-names></name><name name-style="western"><surname>Ragoonanan</surname><given-names>D</given-names></name><name name-style="western"><surname>Yi</surname><given-names>S</given-names></name><name name-style="western"><surname>Swinford</surname><given-names>R</given-names></name><name name-style="western"><surname>Petropoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Mahadeo</surname><given-names>KM</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>The organ trail: a review of biomarkers of organ failure</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>579219</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.579219</pub-id><pub-id pub-id-type="pmid">33262945</pub-id><pub-id pub-id-type="pmcid">PMC7686565</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Dao L, Ragoonanan D, Yi S, Swinford R, Petropoulos D, Mahadeo KM, Li S. The organ trail: a review of biomarkers of organ failure. Front Oncol. 2020;10: 579219.<pub-id pub-id-type="pmid">33262945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.579219</pub-id><pub-id pub-id-type="pmcid">PMC7686565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aulin</surname><given-names>LBS</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>DW</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>MAA</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>V&#246;ller</surname><given-names>S</given-names></name><name name-style="western"><surname>van Hasselt</surname><given-names>JGC</given-names></name></person-group><article-title>Biomarker-guided individualization of antibiotic therapy</article-title><source>Clin Pharmacol Ther</source><year>2021</year><volume>110</volume><issue>2</issue><fpage>346</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1002/cpt.2194</pub-id><pub-id pub-id-type="pmid">33559152</pub-id><pub-id pub-id-type="pmcid">PMC8359228</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Aulin LBS, de Lange DW, Saleh MAA, van der Graaf PH, V&#246;ller S, van Hasselt JGC. Biomarker-guided individualization of antibiotic therapy. Clin Pharmacol Ther. 2021;110(2):346&#8211;60.<pub-id pub-id-type="pmid">33559152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2194</pub-id><pub-id pub-id-type="pmcid">PMC8359228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bramer</surname><given-names>WM</given-names></name><name name-style="western"><surname>Giustini</surname><given-names>D</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>GB</given-names></name><name name-style="western"><surname>Holland</surname><given-names>L</given-names></name><name name-style="western"><surname>Bekhuis</surname><given-names>T</given-names></name></person-group><article-title>De-duplication of database search results for systematic reviews in EndNote</article-title><source>J Med Libr Assoc</source><year>2016</year><volume>104</volume><issue>3</issue><fpage>240</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.3163/1536-5050.104.3.014</pub-id><pub-id pub-id-type="pmid">27366130</pub-id><pub-id pub-id-type="pmcid">PMC4915647</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240&#8211;3.<pub-id pub-id-type="pmid">27366130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3163/1536-5050.104.3.014</pub-id><pub-id pub-id-type="pmcid">PMC4915647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoergenhofer</surname><given-names>C</given-names></name><name name-style="western"><surname>Hobl</surname><given-names>EL</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>T</given-names></name><name name-style="western"><surname>Speidl</surname><given-names>WS</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>G</given-names></name><name name-style="western"><surname>Siller-Matula</surname><given-names>J</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>C</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>B</given-names></name><name name-style="western"><surname>Kubica</surname><given-names>J</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Prasugrel in critically ill patients</article-title><source>Thromb Haemost</source><year>2017</year><volume>117</volume><issue>8</issue><fpage>1582</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1160/TH17-03-0154</pub-id><pub-id pub-id-type="pmid">28692105</pub-id><pub-id pub-id-type="pmcid">PMC6292180</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Schoergenhofer C, Hobl EL, Staudinger T, Speidl WS, Heinz G, Siller-Matula J, Zauner C, Reiter B, Kubica J, Jilma B. Prasugrel in critically ill patients. Thromb Haemost. 2017;117(8):1582&#8211;7.<pub-id pub-id-type="pmid">28692105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1160/TH17-03-0154</pub-id><pub-id pub-id-type="pmcid">PMC6292180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oudemans-van Straaten</surname><given-names>HM</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Attema-de Jonge</surname><given-names>ME</given-names></name><name name-style="western"><surname>van Ogtrop</surname><given-names>ML</given-names></name><name name-style="western"><surname>Zandstra</surname><given-names>DF</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>EJ</given-names></name></person-group><article-title>Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><issue>5</issue><fpage>R240</fpage><pub-id pub-id-type="doi">10.1186/cc10489</pub-id><pub-id pub-id-type="pmid">22004661</pub-id><pub-id pub-id-type="pmcid">PMC3334791</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Oudemans-van Straaten HM, Endeman H, Bosman RJ, Attema-de Jonge ME, van Ogtrop ML, Zandstra DF, Franssen EJ. Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study. Crit Care. 2011;15(5):R240.<pub-id pub-id-type="pmid">22004661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc10489</pub-id><pub-id pub-id-type="pmcid">PMC3334791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Bedard</surname><given-names>E</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>SH</given-names></name></person-group><article-title>Bioavailability of orally administered drugs in critically Ill patients</article-title><source>J Pharm Pract</source><year>2023</year><volume>36</volume><issue>4</issue><fpage>967</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1177/08971900221100205</pub-id><pub-id pub-id-type="pmid">35521821</pub-id><pub-id pub-id-type="pmcid">PMC10350721</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Forsberg J, Bedard E, Mahmoud SH. Bioavailability of orally administered drugs in critically Ill patients. J Pharm Pract. 2023;36(4):967&#8211;79.<pub-id pub-id-type="pmid">35521821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08971900221100205</pub-id><pub-id pub-id-type="pmcid">PMC10350721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramnarain</surname><given-names>D</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>DW</given-names></name><name name-style="western"><surname>Meulenbelt</surname><given-names>J</given-names></name></person-group><article-title>Acute renal failure due to tobramycin intoxication during selective digestive tract decontamination</article-title><source>Intensive Care Med</source><year>2011</year><volume>37</volume><issue>8</issue><fpage>1386</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1007/s00134-011-2242-0</pub-id><pub-id pub-id-type="pmid">21590348</pub-id><pub-id pub-id-type="pmcid">PMC3136690</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ramnarain D, de Lange DW, Meulenbelt J. Acute renal failure due to tobramycin intoxication during selective digestive tract decontamination. Intensive Care Med. 2011;37(8):1386&#8211;7.<pub-id pub-id-type="pmid">21590348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-011-2242-0</pub-id><pub-id pub-id-type="pmcid">PMC3136690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Navajas</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>NJ</given-names></name></person-group><article-title>The digestive tract as the origin of systemic inflammation</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>279</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1458-3</pub-id><pub-id pub-id-type="pmid">27751165</pub-id><pub-id pub-id-type="pmcid">PMC5067918</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">de Jong PR, Gonz&#225;lez-Navajas JM, Jansen NJ. The digestive tract as the origin of systemic inflammation. Crit Care. 2016;20(1):279.<pub-id pub-id-type="pmid">27751165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-016-1458-3</pub-id><pub-id pub-id-type="pmcid">PMC5067918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polito</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamitouche</surname><given-names>N</given-names></name><name name-style="western"><surname>Ribot</surname><given-names>M</given-names></name><name name-style="western"><surname>Polito</surname><given-names>A</given-names></name><name name-style="western"><surname>Laviolle</surname><given-names>B</given-names></name><name name-style="western"><surname>Bellissant</surname><given-names>E</given-names></name><name name-style="western"><surname>Annane</surname><given-names>D</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>JC</given-names></name></person-group><article-title>Pharmacokinetics of oral fludrocortisone in septic shock</article-title><source>Br J Clin Pharmacol</source><year>2016</year><volume>82</volume><issue>6</issue><fpage>1509</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1111/bcp.13065</pub-id><pub-id pub-id-type="pmid">27416887</pub-id><pub-id pub-id-type="pmcid">PMC5099539</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Polito A, Hamitouche N, Ribot M, Polito A, Laviolle B, Bellissant E, Annane D, Alvarez JC. Pharmacokinetics of oral fludrocortisone in septic shock. Br J Clin Pharmacol. 2016;82(6):1509&#8211;16.<pub-id pub-id-type="pmid">27416887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13065</pub-id><pub-id pub-id-type="pmcid">PMC5099539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoergenhofer</surname><given-names>C</given-names></name><name name-style="western"><surname>Hobl</surname><given-names>EL</given-names></name><name name-style="western"><surname>Schwameis</surname><given-names>M</given-names></name><name name-style="western"><surname>Gelbenegger</surname><given-names>G</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>T</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>G</given-names></name><name name-style="western"><surname>Speidl</surname><given-names>WS</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>C</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>B</given-names></name><name name-style="western"><surname>Lang</surname><given-names>I</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial</article-title><source>Eur J Clin Invest</source><year>2017</year><volume>47</volume><issue>7</issue><fpage>504</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1111/eci.12771</pub-id><pub-id pub-id-type="pmid">28556061</pub-id><pub-id pub-id-type="pmcid">PMC5519937</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Schoergenhofer C, Hobl EL, Schwameis M, Gelbenegger G, Staudinger T, Heinz G, Speidl WS, Zauner C, Reiter B, Lang I, Jilma B. Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. Eur J Clin Invest. 2017;47(7):504&#8211;12.<pub-id pub-id-type="pmid">28556061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/eci.12771</pub-id><pub-id pub-id-type="pmcid">PMC5519937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekker</surname><given-names>MJE</given-names></name><name name-style="western"><surname>van der Sande</surname><given-names>FM</given-names></name><name name-style="western"><surname>van den Berghe</surname><given-names>F</given-names></name><name name-style="western"><surname>Leunissen</surname><given-names>KML</given-names></name><name name-style="western"><surname>Kooman</surname><given-names>JP</given-names></name></person-group><article-title>Fluid overload and inflammation axis</article-title><source>Blood Purif</source><year>2018</year><volume>45</volume><issue>1&#8211;3</issue><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1159/000485153</pub-id><pub-id pub-id-type="pmid">29478061</pub-id><pub-id pub-id-type="pmcid">PMC6492921</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Dekker MJE, van der Sande FM, van den Berghe F, Leunissen KML, Kooman JP. Fluid overload and inflammation axis. Blood Purif. 2018;45(1&#8211;3):159&#8211;65.<pub-id pub-id-type="pmid">29478061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000485153</pub-id><pub-id pub-id-type="pmcid">PMC6492921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Docsa</surname><given-names>T</given-names></name><name name-style="western"><surname>Sipos</surname><given-names>A</given-names></name><name name-style="western"><surname>Cox</surname><given-names>CS</given-names></name><name name-style="western"><surname>Uray</surname><given-names>K</given-names></name></person-group><article-title>The role of inflammatory mediators in the development of gastrointestinal motility disorders</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>13</issue><fpage>6917</fpage><pub-id pub-id-type="doi">10.3390/ijms23136917</pub-id><pub-id pub-id-type="pmid">35805922</pub-id><pub-id pub-id-type="pmcid">PMC9266627</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Docsa T, Sipos A, Cox CS, Uray K. The role of inflammatory mediators in the development of gastrointestinal motility disorders. Int J Mol Sci. 2022;23(13):6917.<pub-id pub-id-type="pmid">35805922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23136917</pub-id><pub-id pub-id-type="pmcid">PMC9266627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govil</surname><given-names>D</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D</given-names></name></person-group><article-title>Gastrointestinal motility disorders in critically Ill</article-title><source>Indian J Crit Care Med</source><year>2020</year><volume>24</volume><issue>Suppl 4</issue><fpage>S179</fpage><lpage>S182</lpage><pub-id pub-id-type="pmid">33354038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23614</pub-id><pub-id pub-id-type="pmcid">PMC7724947</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Govil D, Pal D. Gastrointestinal motility disorders in critically Ill. Indian J Crit Care Med. 2020;24(Suppl 4):S179&#8211;82.<pub-id pub-id-type="pmid">33354038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23614</pub-id><pub-id pub-id-type="pmcid">PMC7724947</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechuga</surname><given-names>S</given-names></name><name name-style="western"><surname>Braga-Neto</surname><given-names>MB</given-names></name><name name-style="western"><surname>Naydenov</surname><given-names>NG</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>F</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>AI</given-names></name></person-group><article-title>Understanding disruption of the gut barrier during inflammation: should we abandon traditional epithelial cell lines and switch to intestinal organoids?</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1108289</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1108289</pub-id><pub-id pub-id-type="pmid">36875103</pub-id><pub-id pub-id-type="pmcid">PMC9983034</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Lechuga S, Braga-Neto MB, Naydenov NG, Rieder F, Ivanov AI. Understanding disruption of the gut barrier during inflammation: should we abandon traditional epithelial cell lines and switch to intestinal organoids? Front Immunol. 2023;14:1108289.<pub-id pub-id-type="pmid">36875103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1108289</pub-id><pub-id pub-id-type="pmcid">PMC9983034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reintam Blaser</surname><given-names>A</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>JC</given-names></name><name name-style="western"><surname>Fruhwald</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Wernerman</surname><given-names>J</given-names></name><name name-style="western"><surname>Benstoem</surname><given-names>C</given-names></name><name name-style="western"><surname>Casaer</surname><given-names>MP</given-names></name><name name-style="western"><surname>Starkopf</surname><given-names>J</given-names></name><name name-style="western"><surname>van Zanten</surname><given-names>A</given-names></name><name name-style="western"><surname>Rooyackers</surname><given-names>O</given-names></name><etal/></person-group><article-title>Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the section of metabolism, endocrinology and nutrition of the European society of intensive care medicine</article-title><source>Crit Care</source><year>2020</year><volume>24</volume><issue>1</issue><fpage>224</fpage><pub-id pub-id-type="doi">10.1186/s13054-020-02889-4</pub-id><pub-id pub-id-type="pmid">32414423</pub-id><pub-id pub-id-type="pmcid">PMC7226709</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Reintam Blaser A, Preiser JC, Fruhwald S, Wilmer A, Wernerman J, Benstoem C, Casaer MP, Starkopf J, van Zanten A, Rooyackers O, et al. Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the section of metabolism, endocrinology and nutrition of the European society of intensive care medicine. Crit Care. 2020;24(1):224.<pub-id pub-id-type="pmid">32414423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-02889-4</pub-id><pub-id pub-id-type="pmcid">PMC7226709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartelink</surname><given-names>IH</given-names></name><name name-style="western"><surname>Bet</surname><given-names>PM</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>N</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Duijvelaar</surname><given-names>E</given-names></name><name name-style="western"><surname>Grob</surname><given-names>B</given-names></name><name name-style="western"><surname>Honeywell</surname><given-names>R</given-names></name><name name-style="western"><surname>Evelo</surname><given-names>A</given-names></name><name name-style="western"><surname>Tielbeek</surname><given-names>IPE</given-names></name><name name-style="western"><surname>Snape</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCOVID&#8212;imatinib study</article-title><source>CPT Pharm Syst Pharmacol</source><year>2021</year><volume>10</volume><issue>12</issue><fpage>1497</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1002/psp4.12718</pub-id><pub-id pub-id-type="pmcid">PMC8646516</pub-id><pub-id pub-id-type="pmid">34608769</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Bartelink IH, Bet PM, Widmer N, Guidi M, Duijvelaar E, Grob B, Honeywell R, Evelo A, Tielbeek IPE, Snape SD, et al. Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCOVID&#8212;imatinib study. CPT Pharm Syst Pharmacol. 2021;10(12):1497&#8211;511.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12718</pub-id><pub-id pub-id-type="pmcid">PMC8646516</pub-id><pub-id pub-id-type="pmid">34608769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahrami</surname><given-names>B</given-names></name><name name-style="western"><surname>Sefidani Forough</surname><given-names>A</given-names></name><name name-style="western"><surname>Khezrnia</surname><given-names>SS</given-names></name><name name-style="western"><surname>Najmeddin</surname><given-names>F</given-names></name><name name-style="western"><surname>Arabzadeh</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rouini</surname><given-names>MR</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mojtahedzadeh</surname><given-names>M</given-names></name></person-group><article-title>Relationship between amikacin pharmacokinetics and biological parameters associated with organ dysfunction: a case series study of critically ill patients with intra-abdominal sepsis</article-title><source>Eur J Hosp Pharm</source><year>2022</year><volume>29</volume><issue>e1</issue><fpage>e72</fpage><lpage>e76</lpage><pub-id pub-id-type="doi">10.1136/ejhpharm-2021-003089</pub-id><pub-id pub-id-type="pmid">34764144</pub-id><pub-id pub-id-type="pmcid">PMC8899638</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Shahrami B, Sefidani Forough A, Khezrnia SS, Najmeddin F, Arabzadeh AA, Rouini MR, Najafi A, Mojtahedzadeh M. Relationship between amikacin pharmacokinetics and biological parameters associated with organ dysfunction: a case series study of critically ill patients with intra-abdominal sepsis. Eur J Hosp Pharm. 2022;29(e1):e72&#8211;6.<pub-id pub-id-type="pmid">34764144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ejhpharm-2021-003089</pub-id><pub-id pub-id-type="pmcid">PMC8899638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngougni Pokem</surname><given-names>P</given-names></name><name name-style="western"><surname>Matzneller</surname><given-names>P</given-names></name><name name-style="western"><surname>Vervaeke</surname><given-names>S</given-names></name><name name-style="western"><surname>Wittebole</surname><given-names>X</given-names></name><name name-style="western"><surname>Goeman</surname><given-names>L</given-names></name><name name-style="western"><surname>Coessens</surname><given-names>M</given-names></name><name name-style="western"><surname>Cottone</surname><given-names>E</given-names></name><name name-style="western"><surname>Capron</surname><given-names>A</given-names></name><name name-style="western"><surname>Wulkersdorfer</surname><given-names>B</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P</given-names></name><etal/></person-group><article-title>Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications</article-title><source>J Antimicrob Chemother</source><year>2022</year><volume>77</volume><issue>10</issue><fpage>2742</fpage><lpage>2753</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac286</pub-id><pub-id pub-id-type="pmid">36018077</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Ngougni Pokem P, Matzneller P, Vervaeke S, Wittebole X, Goeman L, Coessens M, Cottone E, Capron A, Wulkersdorfer B, Wallemacq P, et al. Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications. J Antimicrob Chemother. 2022;77(10):2742&#8211;53.<pub-id pub-id-type="pmid">36018077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkac286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;nig</surname><given-names>C</given-names></name><name name-style="western"><surname>Grensemann</surname><given-names>J</given-names></name><name name-style="western"><surname>Czorlich</surname><given-names>P</given-names></name><name name-style="western"><surname>Schlemm</surname><given-names>E</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>S</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>SG</given-names></name></person-group><article-title>A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis</article-title><source>Clin Microbiol Infect</source><year>2022</year><volume>28</volume><issue>7</issue><fpage>1022</fpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.02.017</pub-id><pub-id pub-id-type="pmid">35182756</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">K&#246;nig C, Grensemann J, Czorlich P, Schlemm E, Kluge S, Wicha SG. A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis. Clin Microbiol Infect. 2022;28(7):1022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2022.02.017</pub-id><pub-id pub-id-type="pmid">35182756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Voort</surname><given-names>PH</given-names></name><name name-style="western"><surname>Boerma</surname><given-names>EC</given-names></name><name name-style="western"><surname>Yska</surname><given-names>JP</given-names></name></person-group><article-title>Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>59</volume><issue>5</issue><fpage>952</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm074</pub-id><pub-id pub-id-type="pmid">17389717</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59(5):952&#8211;6.<pub-id pub-id-type="pmid">17389717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkm074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goytia</surname><given-names>GL</given-names></name><name name-style="western"><surname>Lares-Asseff</surname><given-names>I</given-names></name><name name-style="western"><surname>Guille</surname><given-names>MGP</given-names></name><name name-style="western"><surname>Perez</surname><given-names>AG</given-names></name><name name-style="western"><surname>Mejia</surname><given-names>CL</given-names></name></person-group><article-title>Relationship between clinical and biologic variables and chloramphenicol pharmacokinetic parameters in pediatric patients with sepsis</article-title><source>Ann Pharmacother</source><year>2000</year><volume>34</volume><issue>3</issue><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1345/aph.19050</pub-id><pub-id pub-id-type="pmid">10917389</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Goytia GL, Lares-Asseff I, Guille MGP, Perez AG, Mejia CL. Relationship between clinical and biologic variables and chloramphenicol pharmacokinetic parameters in pediatric patients with sepsis. Ann Pharmacother. 2000;34(3):393&#8211;7.<pub-id pub-id-type="pmid">10917389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.19050</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goralski</surname><given-names>KB</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Landry</surname><given-names>K</given-names></name><name name-style="western"><surname>Issa</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sleno</surname><given-names>L</given-names></name><name name-style="western"><surname>Julien</surname><given-names>LC</given-names></name><name name-style="western"><surname>Wood</surname><given-names>J</given-names></name><name name-style="western"><surname>Hall</surname><given-names>RI</given-names></name></person-group><article-title>An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid</article-title><source>Can J Anaesth</source><year>2017</year><volume>64</volume><issue>10</issue><fpage>1009</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1007/s12630-017-0933-x</pub-id><pub-id pub-id-type="pmid">28710563</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Wang Y, Goralski KB, Roberts DJ, Landry K, Issa ME, Sleno L, Julien LC, Wood J, Hall RI. An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid. Can J Anaesth. 2017;64(10):1009&#8211;22.<pub-id pub-id-type="pmid">28710563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12630-017-0933-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Goralski</surname><given-names>KB</given-names></name><name name-style="western"><surname>Renton</surname><given-names>KW</given-names></name><name name-style="western"><surname>Julien</surname><given-names>LC</given-names></name><name name-style="western"><surname>Webber</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sleno</surname><given-names>L</given-names></name><name name-style="western"><surname>Volmer</surname><given-names>DA</given-names></name><name name-style="western"><surname>Hall</surname><given-names>RI</given-names></name></person-group><article-title>Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><issue>10</issue><fpage>2767</fpage><lpage>2774</lpage><pub-id pub-id-type="pmid">19865006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3181b755d5</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Roberts DJ, Goralski KB, Renton KW, Julien LC, Webber AM, Sleno L, Volmer DA, Hall RI. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain. Crit Care Med. 2009;37(10):2767&#8211;74.<pub-id pub-id-type="pmid">19865006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3181b755d5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isla</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Troc&#243;niz</surname><given-names>IF</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L</given-names></name><name name-style="western"><surname>Solin&#237;s</surname><given-names>MA</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J</given-names></name><name name-style="western"><surname>S&#225;nchez-Izquierdo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pedraz</surname><given-names>JL</given-names></name></person-group><article-title>Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy</article-title><source>Clin Pharmacokinet</source><year>2008</year><volume>47</volume><issue>3</issue><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.2165/00003088-200847030-00003</pub-id><pub-id pub-id-type="pmid">18307371</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Isla A, Rodr&#237;guez-Gasc&#243;n A, Troc&#243;niz IF, Bueno L, Solin&#237;s MA, Maynar J, S&#225;nchez-Izquierdo JA, Pedraz JL. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008;47(3):173&#8211;80.<pub-id pub-id-type="pmid">18307371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200847030-00003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>M</given-names></name></person-group><article-title>Pharmacokinetic analysis investigating gentamicin dosing in a major burned patient complicated by septic shock</article-title><source>J Chemother</source><year>2020</year><volume>32</volume><issue>4</issue><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1080/1120009X.2020.1733335</pub-id><pub-id pub-id-type="pmid">32124673</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Gatti M. Pharmacokinetic analysis investigating gentamicin dosing in a major burned patient complicated by septic shock. J Chemother. 2020;32(4):208&#8211;12.<pub-id pub-id-type="pmid">32124673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/1120009X.2020.1733335</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>MG</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>MO</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>What are the current approaches to optimising antimicrobial dosing in the intensive care unit?</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><issue>7</issue><fpage>638</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics12070638</pub-id><pub-id pub-id-type="pmid">32645953</pub-id><pub-id pub-id-type="pmcid">PMC7407796</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Chai MG, Cotta MO, Abdul-Aziz MH, Roberts JA. What are the current approaches to optimising antimicrobial dosing in the intensive care unit? Pharmaceutics. 2020;12(7):638.<pub-id pub-id-type="pmid">32645953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics12070638</pub-id><pub-id pub-id-type="pmcid">PMC7407796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulldemolins</surname><given-names>M</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name></person-group><article-title>The relevance of drug volume of distribution in antibiotic dosing</article-title><source>Curr Pharm Biotechnol</source><year>2011</year><volume>12</volume><issue>12</issue><fpage>1996</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.2174/138920111798808365</pub-id><pub-id pub-id-type="pmid">21554218</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Ulldemolins M, Rello J. The relevance of drug volume of distribution in antibiotic dosing. Curr Pharm Biotechnol. 2011;12(12):1996&#8211;2001.<pub-id pub-id-type="pmid">21554218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920111798808365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dufour</surname><given-names>G</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetics of antibiotics or antifungal drugs in intensive care units</article-title><source>Curr Infect Dis Rep</source><year>2009</year><volume>11</volume><issue>1</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s11908-009-0003-9</pub-id><pub-id pub-id-type="pmid">19094820</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Dufour G, Montravers P. Pharmacokinetics of antibiotics or antifungal drugs in intensive care units. Curr Infect Dis Rep. 2009;11(1):14&#8211;20.<pub-id pub-id-type="pmid">19094820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11908-009-0003-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosein</surname><given-names>S</given-names></name><name name-style="western"><surname>Udy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>Physiological changes in the critically ill patient with sepsis</article-title><source>Curr Pharm Biotechnol</source><year>2011</year><volume>12</volume><issue>12</issue><fpage>1991</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.2174/138920111798808248</pub-id><pub-id pub-id-type="pmid">21554219</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient with sepsis. Curr Pharm Biotechnol. 2011;12(12):1991&#8211;5.<pub-id pub-id-type="pmid">21554219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920111798808248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macedo</surname><given-names>RS</given-names></name><name name-style="western"><surname>Onita</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wille</surname><given-names>MP</given-names></name><name name-style="western"><surname>Furtado</surname><given-names>GH</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of antimicrobial drugs in intensive care unit patients</article-title><source>Shock</source><year>2013</year><volume>39</volume><issue>Suppl 1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e31828faec0</pub-id><pub-id pub-id-type="pmid">23481498</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Macedo RS, Onita JH, Wille MP, Furtado GH. Pharmacokinetics and pharmacodynamics of antimicrobial drugs in intensive care unit patients. Shock. 2013;39(Suppl 1):24&#8211;8.<pub-id pub-id-type="pmid">23481498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0b013e31828faec0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetic issues for antibiotics in the critically ill patient</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><issue>3</issue><fpage>840</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181961bff</pub-id><pub-id pub-id-type="pmid">19237886</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840&#8211;51.<pub-id pub-id-type="pmid">19237886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3181961bff</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denaro</surname><given-names>CP</given-names></name><name name-style="western"><surname>Ravenscroft</surname><given-names>PJ</given-names></name></person-group><article-title>Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients</article-title><source>Aust N Z J Med</source><year>1987</year><volume>17</volume><issue>5</issue><fpage>526</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1111/j.1445-5994.1987.tb00114.x</pub-id><pub-id pub-id-type="pmid">3446165</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Denaro CP, Ravenscroft PJ. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Aust N Z J Med. 1987;17(5):526&#8211;32.<pub-id pub-id-type="pmid">3446165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1445-5994.1987.tb00114.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chelluri</surname><given-names>L</given-names></name><name name-style="western"><surname>Jastremski</surname><given-names>MS</given-names></name></person-group><article-title>Inadequacy of standard aminoglycoside loading doses in acutely ill patients</article-title><source>Crit Care Med</source><year>1987</year><volume>15</volume><issue>12</issue><fpage>1143</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1097/00003246-198712000-00015</pub-id><pub-id pub-id-type="pmid">3677767</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med. 1987;15(12):1143&#8211;5.<pub-id pub-id-type="pmid">3677767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-198712000-00015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasta</surname><given-names>JF</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>DK</given-names></name></person-group><article-title>Variability in aminoglycoside pharmacokinetics in critically ill surgical patients</article-title><source>Crit Care Med</source><year>1988</year><volume>16</volume><issue>4</issue><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1097/00003246-198804000-00004</pub-id><pub-id pub-id-type="pmid">3349791</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16(4):327&#8211;30.<pub-id pub-id-type="pmid">3349791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-198804000-00004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>PF</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H</given-names></name><name name-style="western"><surname>Dugernier</surname><given-names>T</given-names></name><name name-style="western"><surname>Delattre</surname><given-names>I</given-names></name><name name-style="western"><surname>Layeux</surname><given-names>B</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>D</given-names></name><name name-style="western"><surname>Wittebole</surname><given-names>X</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F</given-names></name></person-group><article-title>Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>2</issue><fpage>R53</fpage><pub-id pub-id-type="doi">10.1186/cc8945</pub-id><pub-id pub-id-type="pmid">20370907</pub-id><pub-id pub-id-type="pmcid">PMC2887170</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53.<pub-id pub-id-type="pmid">20370907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc8945</pub-id><pub-id pub-id-type="pmcid">PMC2887170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triginer</surname><given-names>C</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>I</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>R</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Torrent</surname><given-names>J</given-names></name><name name-style="western"><surname>Benito</surname><given-names>S</given-names></name><name name-style="western"><surname>Net</surname><given-names>A</given-names></name></person-group><article-title>Gentamicin volume of distribution in critically ill septic patients</article-title><source>Intensive Care Med</source><year>1990</year><volume>16</volume><issue>5</issue><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/BF01706354</pub-id><pub-id pub-id-type="pmid">2212254</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Triginer C, Izquierdo I, Fern&#225;ndez R, Rello J, Torrent J, Benito S, Net A. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16(5):303&#8211;6.<pub-id pub-id-type="pmid">2212254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01706354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemiec</surname><given-names>PW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Allo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Miller</surname><given-names>CF</given-names></name></person-group><article-title>Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care</article-title><source>Arch Surg</source><year>1987</year><volume>122</volume><issue>2</issue><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1001/archsurg.1987.01400140089012</pub-id><pub-id pub-id-type="pmid">3813869</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Niemiec PW Jr, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg. 1987;122(2):207&#8211;12.<pub-id pub-id-type="pmid">3813869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archsurg.1987.01400140089012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zavascki</surname><given-names>AP</given-names></name><name name-style="western"><surname>Klee</surname><given-names>BO</given-names></name><name name-style="western"><surname>Bulitta</surname><given-names>JB</given-names></name></person-group><article-title>Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility</article-title><source>Expert Rev Anti Infect Ther</source><year>2017</year><volume>15</volume><issue>6</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1080/14787210.2017.1316193</pub-id><pub-id pub-id-type="pmid">28375030</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther. 2017;15(6):519&#8211;26.<pub-id pub-id-type="pmid">28375030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14787210.2017.1316193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marik</surname><given-names>PE</given-names></name></person-group><article-title>Aminoglycoside volume of distribution and illness severity in critically ill septic patients</article-title><source>Anaesth Intensive Care</source><year>1993</year><volume>21</volume><issue>2</issue><fpage>172</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1177/0310057X9302100206</pub-id><pub-id pub-id-type="pmid">8517507</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21(2):172&#8211;3.<pub-id pub-id-type="pmid">8517507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0310057X9302100206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckhouse</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>IM</given-names></name><name name-style="western"><surname>Byth</surname><given-names>PL</given-names></name><name name-style="western"><surname>Napier</surname><given-names>JC</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AJ</given-names></name></person-group><article-title>Altered aminoglycoside pharmacokinetics in the critically ill</article-title><source>Anaesth Intensive Care</source><year>1988</year><volume>16</volume><issue>4</issue><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1177/0310057X8801600406</pub-id><pub-id pub-id-type="pmid">3232800</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care. 1988;16(4):418&#8211;22.<pub-id pub-id-type="pmid">3232800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0310057X8801600406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattioli</surname><given-names>F</given-names></name><name name-style="western"><surname>Fucile</surname><given-names>C</given-names></name><name name-style="western"><surname>Del Bono</surname><given-names>V</given-names></name><name name-style="western"><surname>Marini</surname><given-names>V</given-names></name><name name-style="western"><surname>Parisini</surname><given-names>A</given-names></name><name name-style="western"><surname>Molin</surname><given-names>A</given-names></name><name name-style="western"><surname>Zuccoli</surname><given-names>ML</given-names></name><name name-style="western"><surname>Milano</surname><given-names>G</given-names></name><name name-style="western"><surname>Danesi</surname><given-names>R</given-names></name><name name-style="western"><surname>Marchese</surname><given-names>A</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients</article-title><source>Eur J Clin Pharmacol</source><year>2016</year><volume>72</volume><issue>7</issue><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1007/s00228-016-2053-x</pub-id><pub-id pub-id-type="pmid">27048201</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72(7):839&#8211;48.<pub-id pub-id-type="pmid">27048201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-016-2053-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaruratanasirikul</surname><given-names>S</given-names></name><name name-style="western"><surname>Trerayapiwat</surname><given-names>K</given-names></name></person-group><article-title>Meropenem pharmacokinetics during the initial phase of life-threatening infections in critically Ill patients in intensive care units</article-title><source>Pharm Sci Asia</source><year>2019</year><volume>46</volume><issue>2</issue><fpage>129</fpage><pub-id pub-id-type="doi">10.29090/psa.2019.02.017.0066</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Jaruratanasirikul S, Trerayapiwat K. Meropenem pharmacokinetics during the initial phase of life-threatening infections in critically Ill patients in intensive care units. Pharm Sci Asia. 2019;46(2):129.</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Association between pathophysiology and volume of distribution among patients with sepsis or septic shock treated with imipenem: a prospective cohort study</article-title><source>J Infect Dis</source><year>2020</year><volume>221</volume><issue>Suppl 2</issue><fpage>S272</fpage><lpage>S278</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz651</pub-id><pub-id pub-id-type="pmid">32176787</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Huang Y, Yang J, Xie J, Liu L, Liu S, Guo F, Qiu H, Yang Y. Association between pathophysiology and volume of distribution among patients with sepsis or septic shock treated with imipenem: a prospective cohort study. J Infect Dis. 2020;221(Suppl 2):S272&#8211;8.<pub-id pub-id-type="pmid">32176787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viaggi</surname><given-names>B</given-names></name><name name-style="western"><surname>Cangialosi</surname><given-names>A</given-names></name><name name-style="western"><surname>Langer</surname><given-names>M</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>C</given-names></name><name name-style="western"><surname>Gori</surname><given-names>A</given-names></name><name name-style="western"><surname>Corona</surname><given-names>A</given-names></name><name name-style="western"><surname>Finazzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Di Paolo</surname><given-names>A</given-names></name></person-group><article-title>Tissue penetration of antimicrobials in intensive care unit patients: a systematic review&#8212;part II</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><issue>9</issue><fpage>1193</fpage><pub-id pub-id-type="doi">10.3390/antibiotics11091193</pub-id><pub-id pub-id-type="pmid">36139972</pub-id><pub-id pub-id-type="pmcid">PMC9495066</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Viaggi B, Cangialosi A, Langer M, Olivieri C, Gori A, Corona A, Finazzi S, Di Paolo A. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review&#8212;part II. Antibiotics. 2022;11(9):1193.<pub-id pub-id-type="pmid">36139972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics11091193</pub-id><pub-id pub-id-type="pmcid">PMC9495066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finazzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Luci</surname><given-names>G</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>C</given-names></name><name name-style="western"><surname>Langer</surname><given-names>M</given-names></name><name name-style="western"><surname>Mandelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Corona</surname><given-names>A</given-names></name><name name-style="western"><surname>Viaggi</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Paolo</surname><given-names>A</given-names></name></person-group><article-title>Tissue penetration of antimicrobials in intensive care unit patients: a systematic review&#8212;part I</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><issue>9</issue><fpage>1164</fpage><pub-id pub-id-type="doi">10.3390/antibiotics11091164</pub-id><pub-id pub-id-type="pmid">36139944</pub-id><pub-id pub-id-type="pmcid">PMC9495190</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Finazzi S, Luci G, Olivieri C, Langer M, Mandelli G, Corona A, Viaggi B, Di Paolo A. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review&#8212;part I. Antibiotics. 2022;11(9):1164.<pub-id pub-id-type="pmid">36139944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics11091164</pub-id><pub-id pub-id-type="pmcid">PMC9495190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pharmacokinetic/pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with sepsis</article-title><source>J Clin Pharmacol</source><year>2022</year><volume>62</volume><issue>7</issue><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1002/jcph.2031</pub-id><pub-id pub-id-type="pmid">35049077</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Wu C, Zhang X, Xie J, Li Q, He J, Hu L, Wang H, Liu A, Xu J, Yang C, et al. Pharmacokinetic/pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with sepsis. J Clin Pharmacol. 2022;62(7):891&#8211;7.<pub-id pub-id-type="pmid">35049077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.2031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De-Madaria</surname><given-names>E</given-names></name><name name-style="western"><surname>Banks</surname><given-names>PA</given-names></name><name name-style="western"><surname>Moya-Hoyo</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>BU</given-names></name><name name-style="western"><surname>Rey-Riveiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Acevedo-Piedra</surname><given-names>NG</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J</given-names></name><name name-style="western"><surname>Llu&#237;s</surname><given-names>F</given-names></name><name name-style="western"><surname>S&#225;nchez-Pay&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>VK</given-names></name></person-group><article-title>Early factors associated with fluid sequestration and outcomes of patients with acute pancreatitis</article-title><source>Clin Gastroenterol Hepatol</source><year>2014</year><volume>12</volume><issue>6</issue><fpage>997</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2013.10.017</pub-id><pub-id pub-id-type="pmid">24183957</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">De-Madaria E, Banks PA, Moya-Hoyo N, Wu BU, Rey-Riveiro M, Acevedo-Piedra NG, Mart&#237;nez J, Llu&#237;s F, S&#225;nchez-Pay&#225; J, Singh VK. Early factors associated with fluid sequestration and outcomes of patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2014;12(6):997&#8211;1002.<pub-id pub-id-type="pmid">24183957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2013.10.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>A</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>NQ</given-names></name><name name-style="western"><surname>Faghih</surname><given-names>M</given-names></name><name name-style="western"><surname>Afghani</surname><given-names>E</given-names></name><name name-style="western"><surname>Zaheer</surname><given-names>A</given-names></name><name name-style="western"><surname>Khashab</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lennon</surname><given-names>AM</given-names></name><name name-style="western"><surname>De-Madaria</surname><given-names>E</given-names></name><name name-style="western"><surname>Singh</surname><given-names>VK</given-names></name></person-group><article-title>Early predictors of fluid sequestration in acute pancreatitis: a validation study</article-title><source>Pancreas</source><year>2016</year><volume>45</volume><issue>2</issue><fpage>306</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000000444</pub-id><pub-id pub-id-type="pmid">26418903</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Sinha A, V&#225;zquez NQ, Faghih M, Afghani E, Zaheer A, Khashab MA, Lennon AM, De-Madaria E, Singh VK. Early predictors of fluid sequestration in acute pancreatitis: a validation study. Pancreas. 2016;45(2):306&#8211;10.<pub-id pub-id-type="pmid">26418903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPA.0000000000000444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>RK</given-names></name><name name-style="western"><surname>Pande</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>R</given-names></name><name name-style="western"><surname>Trikha</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PM</given-names></name><name name-style="western"><surname>Rewari</surname><given-names>V</given-names></name></person-group><article-title>Effect of change in body weight on clinical outcomes in critically Ill patients</article-title><source>Indian J Crit Care Med</source><year>2021</year><volume>25</volume><issue>9</issue><fpage>1042</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.5005/jp-journals-10071-23978</pub-id><pub-id pub-id-type="pmid">34963724</pub-id><pub-id pub-id-type="pmcid">PMC8664026</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Mishra RK, Pande A, Ramachandran R, Trikha A, Singh PM, Rewari V. Effect of change in body weight on clinical outcomes in critically Ill patients. Indian J Crit Care Med. 2021;25(9):1042&#8211;8.<pub-id pub-id-type="pmid">34963724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23978</pub-id><pub-id pub-id-type="pmcid">PMC8664026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheinenzon</surname><given-names>A</given-names></name><name name-style="western"><surname>Shehadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Michelis</surname><given-names>R</given-names></name><name name-style="western"><surname>Shaoul</surname><given-names>E</given-names></name><name name-style="western"><surname>Ronen</surname><given-names>O</given-names></name></person-group><article-title>Serum albumin levels and inflammation</article-title><source>Int J Biol Macromol</source><year>2021</year><volume>184</volume><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.06.140</pub-id><pub-id pub-id-type="pmid">34181998</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. Int J Biol Macromol. 2021;184:857&#8211;62.<pub-id pub-id-type="pmid">34181998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2021.06.140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soeters</surname><given-names>PB</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>RR</given-names></name><name name-style="western"><surname>Shenkin</surname><given-names>A</given-names></name></person-group><article-title>Hypoalbuminemia: pathogenesis and clinical significance</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2019</year><volume>43</volume><issue>2</issue><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1002/jpen.1451</pub-id><pub-id pub-id-type="pmid">30288759</pub-id><pub-id pub-id-type="pmcid">PMC7379941</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181&#8211;93.<pub-id pub-id-type="pmid">30288759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jpen.1451</pub-id><pub-id pub-id-type="pmcid">PMC7379941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varatharaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Galea</surname><given-names>I</given-names></name></person-group><article-title>The blood-brain barrier in systemic inflammation</article-title><source>Brain Behav Immun</source><year>2017</year><volume>60</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.03.010</pub-id><pub-id pub-id-type="pmid">26995317</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1&#8211;12.<pub-id pub-id-type="pmid">26995317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2016.03.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galea</surname><given-names>I</given-names></name></person-group><article-title>The blood-brain barrier in systemic infection and inflammation</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><issue>11</issue><fpage>2489</fpage><lpage>2501</lpage><pub-id pub-id-type="doi">10.1038/s41423-021-00757-x</pub-id><pub-id pub-id-type="pmid">34594000</pub-id><pub-id pub-id-type="pmcid">PMC8481764</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Galea I. The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18(11):2489&#8211;501.<pub-id pub-id-type="pmid">34594000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-021-00757-x</pub-id><pub-id pub-id-type="pmcid">PMC8481764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatovic</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dimitrijevic</surname><given-names>OB</given-names></name><name name-style="western"><surname>Keep</surname><given-names>RF</given-names></name><name name-style="western"><surname>Andjelkovic</surname><given-names>AV</given-names></name></person-group><article-title>Inflammation and brain edema: new insights into the role of chemokines and their receptors</article-title><source>Acta Neurochir Suppl</source><year>2006</year><volume>96</volume><fpage>444</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1007/3-211-30714-1_91</pub-id><pub-id pub-id-type="pmid">16671502</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV. Inflammation and brain edema: new insights into the role of chemokines and their receptors. Acta Neurochir Suppl. 2006;96:444&#8211;50.<pub-id pub-id-type="pmid">16671502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/3-211-30714-1_91</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>SH</given-names></name><name name-style="western"><surname>Burkett</surname><given-names>A</given-names></name><name name-style="western"><surname>Paz</surname><given-names>A</given-names></name><name name-style="western"><surname>Savarraj</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>S</given-names></name><name name-style="western"><surname>Hergenroeder</surname><given-names>G</given-names></name><name name-style="western"><surname>Gusdon</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HA</given-names></name></person-group><article-title>Systemic inflammatory markers of persistent cerebral edema after aneurysmal subarachnoid hemorrhage</article-title><source>J Neuroinflammation</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>199</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02564-1</pub-id><pub-id pub-id-type="pmid">35927663</pub-id><pub-id pub-id-type="pmcid">PMC9354324</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Ahn SH, Burkett A, Paz A, Savarraj JP, Hinds S, Hergenroeder G, Gusdon AM, Ren X, Hong JH, Choi HA. Systemic inflammatory markers of persistent cerebral edema after aneurysmal subarachnoid hemorrhage. J Neuroinflammation. 2022;19(1):199.<pub-id pub-id-type="pmid">35927663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02564-1</pub-id><pub-id pub-id-type="pmcid">PMC9354324</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hippensteel</surname><given-names>JA</given-names></name><name name-style="western"><surname>Uchimido</surname><given-names>R</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>PD</given-names></name><name name-style="western"><surname>Burke</surname><given-names>RC</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>McMurtry</surname><given-names>SA</given-names></name><name name-style="western"><surname>Colbert</surname><given-names>JF</given-names></name><name name-style="western"><surname>Lindsell</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation</article-title><source>Crit Care</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>259</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2534-2</pub-id><pub-id pub-id-type="pmid">31337421</pub-id><pub-id pub-id-type="pmcid">PMC6652002</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Hippensteel JA, Uchimido R, Tyler PD, Burke RC, Han X, Zhang F, McMurtry SA, Colbert JF, Lindsell CJ, Angus DC, et al. Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. Crit Care. 2019;23(1):259.<pub-id pub-id-type="pmid">31337421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-019-2534-2</pub-id><pub-id pub-id-type="pmcid">PMC6652002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hochepied</surname><given-names>T</given-names></name><name name-style="western"><surname>Berger</surname><given-names>FG</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>H</given-names></name><name name-style="western"><surname>Libert</surname><given-names>C</given-names></name></person-group><article-title>Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties</article-title><source>Cytokine Growth Factor Rev</source><year>2003</year><volume>14</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(02)00054-0</pub-id><pub-id pub-id-type="pmid">12485617</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14(1):25&#8211;34.<pub-id pub-id-type="pmid">12485617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1359-6101(02)00054-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saib</surname><given-names>S</given-names></name><name name-style="western"><surname>Delavenne</surname><given-names>X</given-names></name></person-group><article-title>Inflammation induces changes in the functional expression of P-gp, BCRP, and MRP2: an overview of different models and consequences for drug disposition</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><issue>10</issue><fpage>1544</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13101544</pub-id><pub-id pub-id-type="pmid">34683838</pub-id><pub-id pub-id-type="pmcid">PMC8539483</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Saib S, Delavenne X. Inflammation induces changes in the functional expression of P-gp, BCRP, and MRP2: an overview of different models and consequences for drug disposition. Pharmaceutics. 2021;13(10):1544.<pub-id pub-id-type="pmid">34683838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13101544</pub-id><pub-id pub-id-type="pmcid">PMC8539483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>SD</given-names></name><name name-style="western"><surname>van der Jagt</surname><given-names>M</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BC</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>NG</given-names></name></person-group><article-title>Pharmacokinetics of haloperidol in critically Ill patients: is there an association with inflammation?</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>3</issue><fpage>549</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14030549</pub-id><pub-id pub-id-type="pmid">35335925</pub-id><pub-id pub-id-type="pmcid">PMC8950491</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Li L, Sassen SD, van der Jagt M, Endeman H, Koch BC, Hunfeld NG. Pharmacokinetics of haloperidol in critically Ill patients: is there an association with inflammation? Pharmaceutics. 2022;14(3):549.<pub-id pub-id-type="pmid">35335925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14030549</pub-id><pub-id pub-id-type="pmcid">PMC8950491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neskovic</surname><given-names>N</given-names></name><name name-style="western"><surname>Mandic</surname><given-names>D</given-names></name><name name-style="western"><surname>Marczi</surname><given-names>S</given-names></name><name name-style="western"><surname>Skiljic</surname><given-names>S</given-names></name><name name-style="western"><surname>Kristek</surname><given-names>G</given-names></name><name name-style="western"><surname>Vinkovic</surname><given-names>H</given-names></name><name name-style="western"><surname>Mraovic</surname><given-names>B</given-names></name><name name-style="western"><surname>Debeljak</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kvolik</surname><given-names>S</given-names></name></person-group><article-title>Different pharmacokinetics of tramadol, O-demethyltramadol and N-demethyltramadol in postoperative surgical patients from those observed in medical patients</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>656748</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.656748</pub-id><pub-id pub-id-type="pmid">33935773</pub-id><pub-id pub-id-type="pmcid">PMC8082457</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Neskovic N, Mandic D, Marczi S, Skiljic S, Kristek G, Vinkovic H, Mraovic B, Debeljak Z, Kvolik S. Different pharmacokinetics of tramadol, O-demethyltramadol and N-demethyltramadol in postoperative surgical patients from those observed in medical patients. Front Pharmacol. 2021;12: 656748.<pub-id pub-id-type="pmid">33935773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.656748</pub-id><pub-id pub-id-type="pmcid">PMC8082457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenoir</surname><given-names>C</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rollason</surname><given-names>V</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>F</given-names></name><name name-style="western"><surname>Gloor</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bosilkovska</surname><given-names>M</given-names></name><name name-style="western"><surname>Walder</surname><given-names>B</given-names></name><name name-style="western"><surname>Gabay</surname><given-names>C</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Desmeules</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Impact of acute inflammation on cytochromes P450 activity assessed by the geneva cocktail</article-title><source>Clin Pharmacol Ther</source><year>2021</year><volume>109</volume><issue>6</issue><fpage>1668</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1002/cpt.2146</pub-id><pub-id pub-id-type="pmid">33341941</pub-id><pub-id pub-id-type="pmcid">PMC8247903</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, Walder B, Gabay C, Nissen MJ, Desmeules JA, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the geneva cocktail. Clin Pharmacol Ther. 2021;109(6):1668&#8211;76.<pub-id pub-id-type="pmid">33341941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2146</pub-id><pub-id pub-id-type="pmcid">PMC8247903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macnab</surname><given-names>MS</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Guy</surname><given-names>E</given-names></name><name name-style="western"><surname>Grant</surname><given-names>IS</given-names></name><name name-style="western"><surname>Feely</surname><given-names>J</given-names></name></person-group><article-title>Profound reduction in morphine clearance and liver blood flow in shock</article-title><source>Intensive Care Med</source><year>1986</year><volume>12</volume><issue>5</issue><fpage>366</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/BF00292927</pub-id><pub-id pub-id-type="pmid">3771915</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Macnab MS, Macrae DJ, Guy E, Grant IS, Feely J. Profound reduction in morphine clearance and liver blood flow in shock. Intensive Care Med. 1986;12(5):366&#8211;9.<pub-id pub-id-type="pmid">3771915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00292927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christmas</surname><given-names>P</given-names></name></person-group><article-title>Role of Cytochrome P450s in Inflammation</article-title><source>Adv Pharmacol</source><year>2015</year><volume>74</volume><fpage>163</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/bs.apha.2015.03.005</pub-id><pub-id pub-id-type="pmid">26233907</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Christmas P. Role of Cytochrome P450s in Inflammation. Adv Pharmacol. 2015;74:163&#8211;92.<pub-id pub-id-type="pmid">26233907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apha.2015.03.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>CM</given-names></name></person-group><article-title>Inflammation suppresses patients&#8217; ability to metabolize cytochrome P450 substrate drugs</article-title><source>Ann Pharmacother</source><year>2022</year><volume>56</volume><issue>7</issue><fpage>809</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1177/10600280211047864</pub-id><pub-id pub-id-type="pmid">34590872</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">White CM. Inflammation suppresses patients&#8217; ability to metabolize cytochrome P450 substrate drugs. Ann Pharmacother. 2022;56(7):809&#8211;19.<pub-id pub-id-type="pmid">34590872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10600280211047864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruger</surname><given-names>PS</given-names></name><name name-style="western"><surname>Freir</surname><given-names>NM</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>B</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name></person-group><article-title>A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><issue>4</issue><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1358-3</pub-id><pub-id pub-id-type="pmid">19034423</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med. 2009;35(4):717&#8211;21.<pub-id pub-id-type="pmid">19034423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-008-1358-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakob</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ruokonen</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>PH</given-names></name><name name-style="western"><surname>Takala</surname><given-names>J</given-names></name></person-group><article-title>Effect of dopamine-induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients</article-title><source>Shock</source><year>2002</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00024382-200207000-00001</pub-id><pub-id pub-id-type="pmid">12095126</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Jakob SM, Ruokonen E, Rosenberg PH, Takala J. Effect of dopamine-induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients. Shock. 2002;18(1):1&#8211;7.<pub-id pub-id-type="pmid">12095126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00024382-200207000-00001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toft</surname><given-names>P</given-names></name><name name-style="western"><surname>Heslet</surname><given-names>L</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>M</given-names></name><name name-style="western"><surname>Klitgaard</surname><given-names>NA</given-names></name></person-group><article-title>Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure</article-title><source>Intensive Care Med</source><year>1991</year><volume>17</volume><issue>8</issue><fpage>465</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1007/BF01690768</pub-id><pub-id pub-id-type="pmid">1797890</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Toft P, Heslet L, Hansen M, Klitgaard NA. Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. Intensive Care Med. 1991;17(8):465&#8211;8.<pub-id pub-id-type="pmid">1797890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01690768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berkenstadt</surname><given-names>H</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E</given-names></name><name name-style="western"><surname>Mayan</surname><given-names>H</given-names></name><name name-style="western"><surname>Almog</surname><given-names>S</given-names></name><name name-style="western"><surname>Rotenberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Perel</surname><given-names>A</given-names></name><name name-style="western"><surname>Ezra</surname><given-names>D</given-names></name></person-group><article-title>The pharmacokinetics of morphine and lidocaine in critically ill patients</article-title><source>Intensive Care Med</source><year>1999</year><volume>25</volume><issue>1</issue><fpage>110</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/s001340050796</pub-id><pub-id pub-id-type="pmid">10051088</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Berkenstadt H, Segal E, Mayan H, Almog S, Rotenberg M, Perel A, Ezra D. The pharmacokinetics of morphine and lidocaine in critically ill patients. Intensive Care Med. 1999;25(1):110&#8211;2.<pub-id pub-id-type="pmid">10051088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s001340050796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Fuhs</surname><given-names>DW</given-names></name><name name-style="western"><surname>Cerra</surname><given-names>FB</given-names></name></person-group><article-title>Decreased hepatic clearance of clindamycin in critically ill patients with sepsis</article-title><source>Clin Pharm</source><year>1987</year><volume>6</volume><issue>2</issue><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">3665368</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Mann HJ, Townsend RJ, Fuhs DW, Cerra FB. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm. 1987;6(2):154&#8211;9.<pub-id pub-id-type="pmid">3665368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettersen</surname><given-names>G</given-names></name><name name-style="western"><surname>Mouksassi</surname><given-names>MS</given-names></name><name name-style="western"><surname>Th&#233;or&#234;t</surname><given-names>Y</given-names></name><name name-style="western"><surname>Labb&#233;</surname><given-names>L</given-names></name><name name-style="western"><surname>Faure</surname><given-names>C</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B</given-names></name><name name-style="western"><surname>Litalien</surname><given-names>C</given-names></name></person-group><article-title>Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>67</volume><issue>2</issue><fpage>216</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03328.x</pub-id><pub-id pub-id-type="pmid">19173681</pub-id><pub-id pub-id-type="pmcid">PMC2670379</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Pettersen G, Mouksassi MS, Th&#233;or&#234;t Y, Labb&#233; L, Faure C, Nguyen B, Litalien C. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br J Clin Pharmacol. 2009;67(2):216&#8211;27.<pub-id pub-id-type="pmid">19173681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2008.03328.x</pub-id><pub-id pub-id-type="pmcid">PMC2670379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polyzogopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Amoiridou</surname><given-names>P</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>TP</given-names></name><name name-style="western"><surname>Ventoulis</surname><given-names>I</given-names></name></person-group><article-title>Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review</article-title><source>World J Gastroenterol</source><year>2022</year><volume>28</volume><issue>47</issue><fpage>6662</fpage><lpage>6688</lpage><pub-id pub-id-type="doi">10.3748/wjg.v28.i47.6662</pub-id><pub-id pub-id-type="pmid">36620339</pub-id><pub-id pub-id-type="pmcid">PMC9813941</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Polyzogopoulou E, Amoiridou P, Abraham TP, Ventoulis I. Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. World J Gastroenterol. 2022;28(47):6662&#8211;88.<pub-id pub-id-type="pmid">36620339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v28.i47.6662</pub-id><pub-id pub-id-type="pmcid">PMC9813941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>ET</given-names></name></person-group><article-title>Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics</article-title><source>Clin Pharmacol Ther</source><year>2009</year><volume>85</volume><issue>4</issue><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.302</pub-id><pub-id pub-id-type="pmid">19212314</pub-id><pub-id pub-id-type="pmcid">PMC3139248</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434&#8211;8.<pub-id pub-id-type="pmid">19212314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.302</pub-id><pub-id pub-id-type="pmcid">PMC3139248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>GR</given-names></name></person-group><article-title>Molecular mechanisms of drug metabolism in the critically Ill</article-title><source>Br J Anaesth</source><year>1996</year><volume>77</volume><issue>1</issue><fpage>32</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/bja/77.1.32</pub-id><pub-id pub-id-type="pmid">8703629</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Park GR. Molecular mechanisms of drug metabolism in the critically Ill. Br J Anaesth. 1996;77(1):32&#8211;49.<pub-id pub-id-type="pmid">8703629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/77.1.32</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vet</surname><given-names>NJ</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Tibboel</surname><given-names>D</given-names></name><name name-style="western"><surname>de Wildt</surname><given-names>SN</given-names></name></person-group><article-title>The effect of inflammation on drug metabolism: a focus on pediatrics</article-title><source>Drug Discov Today</source><year>2011</year><volume>16</volume><issue>9&#8211;10</issue><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2011.02.014</pub-id><pub-id pub-id-type="pmid">21376135</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of inflammation on drug metabolism: a focus on pediatrics. Drug Discov Today. 2011;16(9&#8211;10):435&#8211;42.<pub-id pub-id-type="pmid">21376135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2011.02.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>GA</given-names></name><name name-style="western"><surname>Buckman</surname><given-names>SA</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of antimicrobials in critically Ill patients</article-title><source>Surg Infect (Larchmt)</source><year>2018</year><volume>19</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1089/sur.2017.262</pub-id><pub-id pub-id-type="pmid">29272204</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Owen EJ, Gibson GA, Buckman SA. Pharmacokinetics and pharmacodynamics of antimicrobials in critically Ill patients. Surg Infect (Larchmt). 2018;19(2):155&#8211;62.<pub-id pub-id-type="pmid">29272204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/sur.2017.262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>FB</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Optimization of dosing regimens and dosing in special populations</article-title><source>Clin Microbiol Infect</source><year>2015</year><volume>21</volume><issue>10</issue><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.05.002</pub-id><pub-id pub-id-type="pmid">25980350</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect. 2015;21(10):886&#8211;93.<pub-id pub-id-type="pmid">25980350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2015.05.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pletz</surname><given-names>MW</given-names></name><name name-style="western"><surname>Bloos</surname><given-names>F</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>O</given-names></name><name name-style="western"><surname>Brunkhorst</surname><given-names>FM</given-names></name><name name-style="western"><surname>Bode-B&#246;ger</surname><given-names>SM</given-names></name><name name-style="western"><surname>Martens-Lobenhoffer</surname><given-names>J</given-names></name><name name-style="western"><surname>Greer</surname><given-names>MW</given-names></name><name name-style="western"><surname>Stass</surname><given-names>H</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T</given-names></name></person-group><article-title>Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><issue>6</issue><fpage>979</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1007/s00134-010-1864-y</pub-id><pub-id pub-id-type="pmid">20336279</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-B&#246;ger SM, Martens-Lobenhoffer J, Greer MW, Stass H, Welte T. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med. 2010;36(6):979&#8211;83.<pub-id pub-id-type="pmid">20336279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-010-1864-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>S</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>N</given-names></name><name name-style="western"><surname>Smeets</surname><given-names>T</given-names></name><name name-style="western"><surname>Ewoldt</surname><given-names>T</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>SAA</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name></person-group><article-title>Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role?</article-title><source>J Crit Care</source><year>2023</year><volume>78</volume><fpage>154395</fpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2023.154395</pub-id><pub-id pub-id-type="pmid">37542750</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Li L, Sassen S, Hunfeld N, Smeets T, Ewoldt T, van den Berg SAA, Koch BCP, Endeman H. Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role? J Crit Care. 2023;78: 154395.<pub-id pub-id-type="pmid">37542750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2023.154395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name><name name-style="western"><surname>Stader</surname><given-names>F</given-names></name><name name-style="western"><surname>Stoeckle</surname><given-names>M</given-names></name><name name-style="western"><surname>Franzeck</surname><given-names>F</given-names></name><name name-style="western"><surname>Egli</surname><given-names>A</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Hollinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Osthoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Weisser</surname><given-names>M</given-names></name><name name-style="western"><surname>Gebhard</surname><given-names>CE</given-names></name><name name-style="western"><surname>Baettig</surname><given-names>V</given-names></name></person-group><article-title>Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>64</volume><issue>9</issue><fpage>10</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1128/AAC.01177-20</pub-id><pub-id pub-id-type="pmcid">PMC7449226</pub-id><pub-id pub-id-type="pmid">32641296</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, Hollinger A, Osthoff M, Weisser M, Gebhard CE, Baettig V. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. Antimicrob Agents Chemother. 2020;64(9):10&#8211;128.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01177-20</pub-id><pub-id pub-id-type="pmcid">PMC7449226</pub-id><pub-id pub-id-type="pmid">32641296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smeets</surname><given-names>TJL</given-names></name><name name-style="western"><surname>Valkenburg</surname><given-names>AJ</given-names></name><name name-style="western"><surname>van der Jagt</surname><given-names>M</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name><name name-style="western"><surname>Gommers</surname><given-names>D</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>SDT</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>NGM</given-names></name></person-group><article-title>Hyperinflammation reduces midazolam metabolism in critically Ill adults with COVID-19</article-title><source>Clin Pharmacokinet</source><year>2022</year><volume>61</volume><issue>7</issue><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01122-5</pub-id><pub-id pub-id-type="pmid">35397768</pub-id><pub-id pub-id-type="pmcid">PMC8994846</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Smeets TJL, Valkenburg AJ, van der Jagt M, Koch BCP, Endeman H, Gommers D, Sassen SDT, Hunfeld NGM. Hyperinflammation reduces midazolam metabolism in critically Ill adults with COVID-19. Clin Pharmacokinet. 2022;61(7):973&#8211;83.<pub-id pub-id-type="pmid">35397768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-022-01122-5</pub-id><pub-id pub-id-type="pmcid">PMC8994846</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vet</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brussee</surname><given-names>JM</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Mooij</surname><given-names>MG</given-names></name><name name-style="western"><surname>Verlaat</surname><given-names>CW</given-names></name><name name-style="western"><surname>Jerchel</surname><given-names>IS</given-names></name><name name-style="western"><surname>van Schaik</surname><given-names>RH</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BC</given-names></name><name name-style="western"><surname>Tibboel</surname><given-names>D</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Inflammation and organ failure severely affect midazolam clearance in critically Ill children</article-title><source>Am J Respir Crit Care Med</source><year>2016</year><volume>194</volume><issue>1</issue><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1164/rccm.201510-2114OC</pub-id><pub-id pub-id-type="pmid">26796541</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaat CW, Jerchel IS, van Schaik RH, Koch BC, Tibboel D, Knibbe CA, et al. Inflammation and organ failure severely affect midazolam clearance in critically Ill children. Am J Respir Crit Care Med. 2016;194(1):58&#8211;66.<pub-id pub-id-type="pmid">26796541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201510-2114OC</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Carpentier</surname><given-names>EC</given-names></name><name name-style="western"><surname>Canet</surname><given-names>E</given-names></name><name name-style="western"><surname>Masson</surname><given-names>D</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Deslandes</surname><given-names>G</given-names></name><name name-style="western"><surname>Gaultier</surname><given-names>A</given-names></name><name name-style="western"><surname>Dailly</surname><given-names>E</given-names></name><name name-style="western"><surname>Bellouard</surname><given-names>R</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>M</given-names></name></person-group><article-title>Impact of inflammation on midazolam metabolism in severe COVID-19 patients</article-title><source>Clin Pharmacol Ther</source><year>2022</year><volume>112</volume><issue>5</issue><fpage>1033</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1002/cpt.2698</pub-id><pub-id pub-id-type="pmid">35776074</pub-id><pub-id pub-id-type="pmcid">PMC9350233</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Le Carpentier EC, Canet E, Masson D, Martin M, Deslandes G, Gaultier A, Dailly E, Bellouard R, Gregoire M. Impact of inflammation on midazolam metabolism in severe COVID-19 patients. Clin Pharmacol Ther. 2022;112(5):1033&#8211;9.<pub-id pub-id-type="pmid">35776074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2698</pub-id><pub-id pub-id-type="pmcid">PMC9350233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brussee</surname><given-names>JM</given-names></name><name name-style="western"><surname>Vet</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Krekels</surname><given-names>EHJ</given-names></name><name name-style="western"><surname>Valkenburg</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E</given-names></name><name name-style="western"><surname>van Gerven</surname><given-names>JMA</given-names></name><name name-style="western"><surname>Swart</surname><given-names>EL</given-names></name><name name-style="western"><surname>van den Anker</surname><given-names>JN</given-names></name><name name-style="western"><surname>Tibboel</surname><given-names>D</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure</article-title><source>Br J Clin Pharmacol</source><year>2018</year><volume>84</volume><issue>2</issue><fpage>358</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/bcp.13459</pub-id><pub-id pub-id-type="pmid">29072785</pub-id><pub-id pub-id-type="pmcid">PMC5777436</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Brussee JM, Vet NJ, Krekels EHJ, Valkenburg AJ, Jacqz-Aigrain E, van Gerven JMA, Swart EL, van den Anker JN, Tibboel D, de Hoog M, et al. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. Br J Clin Pharmacol. 2018;84(2):358&#8211;68.<pub-id pub-id-type="pmid">29072785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13459</pub-id><pub-id pub-id-type="pmcid">PMC5777436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neupane</surname><given-names>B</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>H</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>T</given-names></name><name name-style="western"><surname>Austin</surname><given-names>R</given-names></name><name name-style="western"><surname>Spooner</surname><given-names>N</given-names></name><name name-style="western"><surname>Rudge</surname><given-names>J</given-names></name><name name-style="western"><surname>Mulla</surname><given-names>H</given-names></name></person-group><article-title>Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: an observational, prospective, controlled study</article-title><source>Pharmacol Res Perspect</source><year>2022</year><volume>10</volume><issue>5</issue><fpage>e01004</fpage><pub-id pub-id-type="doi">10.1002/prp2.1004</pub-id><pub-id pub-id-type="pmid">36036654</pub-id><pub-id pub-id-type="pmcid">PMC9422629</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Neupane B, Pandya H, Pandya T, Austin R, Spooner N, Rudge J, Mulla H. Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: an observational, prospective, controlled study. Pharmacol Res Perspect. 2022;10(5):e01004.<pub-id pub-id-type="pmid">36036654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.1004</pub-id><pub-id pub-id-type="pmcid">PMC9422629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ketharanathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Lili</surname><given-names>A</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>JMP</given-names></name><name name-style="western"><surname>Wildschut</surname><given-names>ED</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>BCM</given-names></name></person-group><article-title>A population pharmacokinetic model of pentobarbital for children with status epilepticus and severe traumatic brain injury</article-title><source>Clin Pharmacokinet</source><year>2023</year><volume>62</volume><issue>7</issue><fpage>1011</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1007/s40262-023-01249-z</pub-id><pub-id pub-id-type="pmid">37247187</pub-id><pub-id pub-id-type="pmcid">PMC10338388</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Ketharanathan N, Lili A, de Vries JMP, Wildschut ED, de Hoog M, Koch BCP, de Winter BCM. A population pharmacokinetic model of pentobarbital for children with status epilepticus and severe traumatic brain injury. Clin Pharmacokinet. 2023;62(7):1011&#8211;22.<pub-id pub-id-type="pmid">37247187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01249-z</pub-id><pub-id pub-id-type="pmcid">PMC10338388</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>J</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>E</given-names></name><name name-style="western"><surname>Peruccioni</surname><given-names>M</given-names></name><name name-style="western"><surname>Marques</surname><given-names>MR</given-names></name><name name-style="western"><surname>Poveda-Andres</surname><given-names>JL</given-names></name><name name-style="western"><surname>Castellanos-Ortega</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>P</given-names></name></person-group><article-title>Impact of voriconazole plasma concentrations on treatment response in critically ill patients</article-title><source>J Clin Pharm Ther</source><year>2019</year><volume>44</volume><issue>4</issue><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12817</pub-id><pub-id pub-id-type="pmid">30851209</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Ruiz J, Gordon M, Villarreal E, Peruccioni M, Marques MR, Poveda-Andres JL, Castellanos-Ortega A, Ramirez P. Impact of voriconazole plasma concentrations on treatment response in critically ill patients. J Clin Pharm Ther. 2019;44(4):572&#8211;8.<pub-id pub-id-type="pmid">30851209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.12817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veringa</surname><given-names>A</given-names></name><name name-style="western"><surname>Ter Avest</surname><given-names>M</given-names></name><name name-style="western"><surname>Span</surname><given-names>LF</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>ER</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Zijlstra</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name></person-group><article-title>Voriconazole metabolism is influenced by severe inflammation: a prospective study</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><issue>1</issue><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw349</pub-id><pub-id pub-id-type="pmid">27601292</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Veringa A, Ter Avest M, Span LF, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JG, van der Werf TS, Alffenaar JC. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72(1):261&#8211;7.<pub-id pub-id-type="pmid">27601292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkw349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>M</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>G</given-names></name><name name-style="western"><surname>Pasquini</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Bartoletti</surname><given-names>M</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name></person-group><article-title>Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-associated pulmonary aspergillosis</article-title><source>Antibiotics.</source><year>2023</year><volume>12</volume><issue>4</issue><fpage>764</fpage><pub-id pub-id-type="doi">10.3390/antibiotics12040764</pub-id><pub-id pub-id-type="pmid">37107125</pub-id><pub-id pub-id-type="pmcid">PMC10134964</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Gatti M, Fornaro G, Pasquini Z, Zanoni A, Bartoletti M, Viale P, Pea F. Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-associated pulmonary aspergillosis. Antibiotics. 2023;12(4):764.<pub-id pub-id-type="pmid">37107125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics12040764</pub-id><pub-id pub-id-type="pmcid">PMC10134964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name></person-group><article-title>Lower prealbumin and higher CRP increase the risk of voriconazole overexposure and adverse reactions</article-title><source>Cureus</source><year>2023</year><volume>15</volume><issue>9</issue><fpage>e46107</fpage><pub-id pub-id-type="pmid">37900477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.46107</pub-id><pub-id pub-id-type="pmcid">PMC10611983</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Lin L, Fu X, Hong M. Lower prealbumin and higher CRP increase the risk of voriconazole overexposure and adverse reactions. Cureus. 2023;15(9): e46107.<pub-id pub-id-type="pmid">37900477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.46107</pub-id><pub-id pub-id-type="pmcid">PMC10611983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Born</surname><given-names>DA</given-names></name><name name-style="western"><surname>M&#228;rtson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Veringa</surname><given-names>A</given-names></name><name name-style="western"><surname>Punt</surname><given-names>NC</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sturkenboom</surname><given-names>MGG</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name></person-group><article-title>Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model</article-title><source>Int J Antimicrob Agents</source><year>2023</year><volume>61</volume><issue>4</issue><fpage>106750</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2023.106750</pub-id><pub-id pub-id-type="pmid">36758777</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">van den Born DA, M&#228;rtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, Sturkenboom MGG, Touw DJ. Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents. 2023;61(4): 106750.<pub-id pub-id-type="pmid">36758777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2023.106750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKindley</surname><given-names>DS</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>BA</given-names></name><name name-style="western"><surname>Hess</surname><given-names>MM</given-names></name><name name-style="western"><surname>Rodman</surname><given-names>JH</given-names></name><name name-style="western"><surname>Feler</surname><given-names>C</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>TC</given-names></name></person-group><article-title>Effect of acute phase response on phenytoin metabolism in neurotrauma patients</article-title><source>J Clin Pharmacol</source><year>1997</year><volume>37</volume><issue>2</issue><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1997.tb04771.x</pub-id><pub-id pub-id-type="pmid">9055139</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">McKindley DS, Boucher BA, Hess MM, Rodman JH, Feler C, Fabian TC. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol. 1997;37(2):129&#8211;39.<pub-id pub-id-type="pmid">9055139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1997.tb04771.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoudi</surname><given-names>L</given-names></name><name name-style="western"><surname>Niknam</surname><given-names>R</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Honarmand</surname><given-names>H</given-names></name><name name-style="western"><surname>Ziaie</surname><given-names>S</given-names></name><name name-style="western"><surname>Mojtahedzadeh</surname><given-names>M</given-names></name></person-group><article-title>Optimal aminoglycoside therapy following the sepsis: how much is too much?</article-title><source>Iran J Pharm Res</source><year>2013</year><volume>12</volume><issue>2</issue><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">24250599</pub-id><pub-id pub-id-type="pmcid">PMC3813230</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Mahmoudi L, Niknam R, Mousavi S, Ahmadi A, Honarmand H, Ziaie S, Mojtahedzadeh M. Optimal aminoglycoside therapy following the sepsis: how much is too much? Iran J Pharm Res. 2013;12(2):261&#8211;9.<pub-id pub-id-type="pmid">24250599</pub-id><pub-id pub-id-type="pmcid">PMC3813230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yost</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Haan</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>KC</given-names></name></person-group><article-title>Increased enoxaparin dosing requirements for treatment of deep vein thrombosis in a severely burned patient: case report and literature review</article-title><source>Pharmacotherapy</source><year>2018</year><volume>38</volume><issue>11</issue><fpage>e82</fpage><lpage>e86</lpage><pub-id pub-id-type="doi">10.1002/phar.2176</pub-id><pub-id pub-id-type="pmid">30129107</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Yost RJ, Haan BJ, Mangan KC. Increased enoxaparin dosing requirements for treatment of deep vein thrombosis in a severely burned patient: case report and literature review. Pharmacotherapy. 2018;38(11):e82&#8211;6.<pub-id pub-id-type="pmid">30129107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptista</surname><given-names>L</given-names></name><name name-style="western"><surname>Moura</surname><given-names>I</given-names></name><name name-style="western"><surname>Silva</surname><given-names>CM</given-names></name><name name-style="western"><surname>Baptista</surname><given-names>JP</given-names></name></person-group><article-title>What is new in augmented renal clearance in septic patients?</article-title><source>Curr Infect Dis Rep</source><year>2023</year><volume>25</volume><issue>11</issue><fpage>255</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s11908-023-00816-6</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Baptista L, Moura I, Silva CM, Baptista JP. What is new in augmented renal clearance in septic patients? Curr Infect Dis Rep. 2023;25(11):255&#8211;72.</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>DM</given-names></name></person-group><article-title>The relevance of drug clearance to antibiotic dosing in critically ill patients</article-title><source>Curr Pharm Biotechnol</source><year>2011</year><volume>12</volume><issue>12</issue><fpage>2002</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.2174/138920111798808374</pub-id><pub-id pub-id-type="pmid">21554217</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Roberts DM. The relevance of drug clearance to antibiotic dosing in critically ill patients. Curr Pharm Biotechnol. 2011;12(12):2002&#8211;14.<pub-id pub-id-type="pmid">21554217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920111798808374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>A</given-names></name><name name-style="western"><surname>Goutelle</surname><given-names>S</given-names></name><name name-style="western"><surname>Que</surname><given-names>YA</given-names></name><name name-style="western"><surname>Eggimann</surname><given-names>P</given-names></name><name name-style="western"><surname>Pantet</surname><given-names>O</given-names></name><name name-style="western"><surname>Sadeghipour</surname><given-names>F</given-names></name><name name-style="western"><surname>Voirol</surname><given-names>P</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C</given-names></name></person-group><article-title>Population pharmacokinetic study of amoxicillin-treated burn patients hospitalized at a swiss tertiary-care center</article-title><source>Antimicrob. Agents Chemother</source><year>2018</year><volume>62</volume><issue>9</issue><fpage>10</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1128/AAC.00505-18</pub-id><pub-id pub-id-type="pmcid">PMC6125536</pub-id><pub-id pub-id-type="pmid">29914948</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Fournier A, Goutelle S, Que YA, Eggimann P, Pantet O, Sadeghipour F, Voirol P, Csajka C. Population pharmacokinetic study of amoxicillin-treated burn patients hospitalized at a swiss tertiary-care center. Antimicrob Agents Chemother. 2018;62(9):10&#8211;128.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00505-18</pub-id><pub-id pub-id-type="pmcid">PMC6125536</pub-id><pub-id pub-id-type="pmid">29914948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zcan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Yegenaga</surname><given-names>I</given-names></name><name name-style="western"><surname>Willke</surname><given-names>A</given-names></name><name name-style="western"><surname>Baykara</surname><given-names>N</given-names></name></person-group><article-title>Multidrug resistance associated with acute kidney injury due to sepsis or systemic inflammatory response syndrome in intensive care unit patients/Yogun Bakim &#220;nitesi Hastalarinda Sepsis veya Sistemik Inflamatuar Sendrom Nedeni ile Gelisen Akut B&#246;brek Hasari ile Iliskili &#199;ogul Ila&#231; Direnci</article-title><source>T&#252;rk Klin Tip Bilimleri Derg</source><year>2013</year><volume>33</volume><issue>2</issue><fpage>485</fpage></element-citation><mixed-citation id="mc-CR136" publication-type="journal">&#214;zcan SK, Yegenaga I, Willke A, Baykara N. Multidrug resistance associated with acute kidney injury due to sepsis or systemic inflammatory response syndrome in intensive care unit patients/Yogun Bakim &#220;nitesi Hastalarinda Sepsis veya Sistemik Inflamatuar Sendrom Nedeni ile Gelisen Akut B&#246;brek Hasari ile Iliskili &#199;ogul Ila&#231; Direnci. T&#252;rk Klin Tip Bilimleri Derg. 2013;33(2):485.</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shikuma</surname><given-names>LR</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>BH</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>RH</given-names></name><name name-style="western"><surname>Solem</surname><given-names>LD</given-names></name><name name-style="western"><surname>Strate</surname><given-names>RG</given-names></name><name name-style="western"><surname>Cerra</surname><given-names>FB</given-names></name><name name-style="western"><surname>Zaske</surname><given-names>DE</given-names></name></person-group><article-title>Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin</article-title><source>Crit Care Med</source><year>1990</year><volume>18</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1097/00003246-199001000-00010</pub-id><pub-id pub-id-type="pmid">2293966</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE. Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med. 1990;18(1):37&#8211;41.<pub-id pub-id-type="pmid">2293966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-199001000-00010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S</given-names></name><name name-style="western"><surname>Forni</surname><given-names>L</given-names></name><name name-style="western"><surname>Joannidis</surname><given-names>M</given-names></name><name name-style="western"><surname>Koyner</surname><given-names>JL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Cantaluppi</surname><given-names>V</given-names></name></person-group><article-title>Pathophysiology of COVID-19-associated acute kidney injury</article-title><source>Nat Rev Nephrol</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>751</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00452-0</pub-id><pub-id pub-id-type="pmid">34226718</pub-id><pub-id pub-id-type="pmcid">PMC8256398</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol. 2021;17(11):751&#8211;64.<pub-id pub-id-type="pmid">34226718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-021-00452-0</pub-id><pub-id pub-id-type="pmcid">PMC8256398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niibe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>N</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>I</given-names></name></person-group><article-title>Identification of factors affecting meropenem pharmacokinetics in critically ill patients: impact of inflammation on clearance</article-title><source>J Infect Chemother</source><year>2022</year><volume>28</volume><issue>4</issue><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2021.12.017</pub-id><pub-id pub-id-type="pmid">34973877</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Niibe Y, Suzuki T, Yamazaki S, Uchida M, Suzuki T, Takahashi N, Hattori N, Nakada TA, Ishii I. Identification of factors affecting meropenem pharmacokinetics in critically ill patients: impact of inflammation on clearance. J Infect Chemother. 2022;28(4):532&#8211;8.<pub-id pub-id-type="pmid">34973877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiac.2021.12.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>SM</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>M</given-names></name></person-group><article-title>Vattimo MdFF: inflammation: improving understanding to prevent or ameliorate kidney diseases</article-title><source>J Venom Anim Toxins Incl Trop Dis</source><year>2021</year><volume>27</volume><fpage>e20200162</fpage><pub-id pub-id-type="pmid">34712277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1678-9199-JVATITD-2020-0162</pub-id><pub-id pub-id-type="pmcid">PMC8525891</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Fernandes SM, Watanabe M. Vattimo MdFF: inflammation: improving understanding to prevent or ameliorate kidney diseases. J Venom Anim Toxins Incl Trop Dis. 2021;27: e20200162.<pub-id pub-id-type="pmid">34712277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1678-9199-JVATITD-2020-0162</pub-id><pub-id pub-id-type="pmcid">PMC8525891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stam</surname><given-names>F</given-names></name><name name-style="western"><surname>van Guldener</surname><given-names>C</given-names></name><name name-style="western"><surname>Schalkwijk</surname><given-names>CG</given-names></name><name name-style="western"><surname>ter Wee</surname><given-names>PM</given-names></name><name name-style="western"><surname>Donker</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Stehouwer</surname><given-names>CD</given-names></name></person-group><article-title>Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><issue>5</issue><fpage>892</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfg080</pub-id><pub-id pub-id-type="pmid">12686661</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003;18(5):892&#8211;8.<pub-id pub-id-type="pmid">12686661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfg080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katip</surname><given-names>W</given-names></name><name name-style="western"><surname>Jaruratanasirikul</surname><given-names>S</given-names></name><name name-style="western"><surname>Pattharachayakul</surname><given-names>S</given-names></name><name name-style="western"><surname>Wongpoowarak</surname><given-names>W</given-names></name><name name-style="western"><surname>Jitsurong</surname><given-names>A</given-names></name><name name-style="western"><surname>Lucksiri</surname><given-names>A</given-names></name></person-group><article-title>The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock</article-title><source>Infect Drug Resist</source><year>2016</year><volume>9</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.2147/IDR.S121513</pub-id><pub-id pub-id-type="pmid">27920562</pub-id><pub-id pub-id-type="pmcid">PMC5125998</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. Infect Drug Resist. 2016;9:253&#8211;60.<pub-id pub-id-type="pmid">27920562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S121513</pub-id><pub-id pub-id-type="pmcid">PMC5125998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minichmayr</surname><given-names>IK</given-names></name><name name-style="western"><surname>Schaeftlein</surname><given-names>A</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>JL</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C</given-names></name></person-group><article-title>Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically Ill patients</article-title><source>Clin Pharmacokinet</source><year>2017</year><volume>56</volume><issue>6</issue><fpage>617</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0463-7</pub-id><pub-id pub-id-type="pmid">27753002</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Minichmayr IK, Schaeftlein A, Kuti JL, Zeitlinger M, Kloft C. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically Ill patients. Clin Pharmacokinet. 2017;56(6):617&#8211;33.<pub-id pub-id-type="pmid">27753002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0463-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>J</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>K</given-names></name><name name-style="western"><surname>Oho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamatani</surname><given-names>A</given-names></name><name name-style="western"><surname>Miyairi</surname><given-names>I</given-names></name></person-group><article-title>Population pharmacokinetics and pharmacodynamics of meropenem in critically Ill pediatric patients</article-title><source>Antimicrob Agents Chemother</source><year>2021</year><volume>65</volume><issue>2</issue><fpage>10</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1128/AAC.01909-20</pub-id><pub-id pub-id-type="pmcid">PMC7848983</pub-id><pub-id pub-id-type="pmid">33199385</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Saito J, Shoji K, Oho Y, Kato H, Matsumoto S, Aoki S, Nakamura H, Ogawa T, Hasegawa M, Yamatani A, Miyairi I. Population pharmacokinetics and pharmacodynamics of meropenem in critically Ill pediatric patients. Antimicrob Agents Chemother. 2021;65(2):10&#8211;128.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01909-20</pub-id><pub-id pub-id-type="pmcid">PMC7848983</pub-id><pub-id pub-id-type="pmid">33199385</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Digvijay</surname><given-names>K</given-names></name><name name-style="western"><surname>Neri</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>V</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>C</given-names></name></person-group><article-title>How does continuous renal replacement therapy affect septic acute kidney injury?</article-title><source>Blood Purif</source><year>2018</year><volume>46</volume><issue>4</issue><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1159/000492026</pub-id><pub-id pub-id-type="pmid">30173223</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Zhang J, Tian J, Sun H, Digvijay K, Neri M, Bhargava V, Yin Y, Ronco C. How does continuous renal replacement therapy affect septic acute kidney injury? Blood Purif. 2018;46(4):326&#8211;31.<pub-id pub-id-type="pmid">30173223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000492026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>VP</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>BG</given-names></name></person-group><article-title>Fluid overload and acute kidney injury</article-title><source>Indian J Crit Care Med</source><year>2020</year><volume>24</volume><issue>Suppl 3</issue><fpage>S94</fpage><lpage>S97</lpage><pub-id pub-id-type="pmid">32704211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23401</pub-id><pub-id pub-id-type="pmcid">PMC7347067</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Patil VP, Salunke BG. Fluid overload and acute kidney injury. Indian J Crit Care Med. 2020;24(Suppl 3):S94&#8211;7.<pub-id pub-id-type="pmid">32704211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23401</pub-id><pub-id pub-id-type="pmcid">PMC7347067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claure-Del Granado</surname><given-names>R</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>RL</given-names></name></person-group><article-title>Fluid overload in the ICU: evaluation and management</article-title><source>BMC Nephrol</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s12882-016-0323-6</pub-id><pub-id pub-id-type="pmid">27484681</pub-id><pub-id pub-id-type="pmcid">PMC4970195</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Claure-Del Granado R, Mehta RL. Fluid overload in the ICU: evaluation and management. BMC Nephrol. 2016;17(1):109.<pub-id pub-id-type="pmid">27484681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-016-0323-6</pub-id><pub-id pub-id-type="pmcid">PMC4970195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pa&#345;&#237;zkov&#225;</surname><given-names>R</given-names></name><name name-style="western"><surname>Mart&#237;nkov&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Havel</surname><given-names>E</given-names></name><name name-style="western"><surname>&#352;afr&#225;nek</surname><given-names>P</given-names></name><name name-style="western"><surname>Ka&#353;ka</surname><given-names>M</given-names></name><name name-style="western"><surname>Astapenko</surname><given-names>D</given-names></name><name name-style="western"><surname>Bezou&#353;ka</surname><given-names>J</given-names></name><name name-style="western"><surname>Chl&#225;dek</surname><given-names>J</given-names></name><name name-style="western"><surname>&#268;ern&#253;</surname><given-names>V</given-names></name></person-group><article-title>Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis</article-title><source>Crit Care</source><year>2021</year><volume>25</volume><issue>1</issue><fpage>251</fpage><pub-id pub-id-type="doi">10.1186/s13054-021-03680-9</pub-id><pub-id pub-id-type="pmid">34274013</pub-id><pub-id pub-id-type="pmcid">PMC8285835</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Pa&#345;&#237;zkov&#225; R, Mart&#237;nkov&#225; J, Havel E, &#352;afr&#225;nek P, Ka&#353;ka M, Astapenko D, Bezou&#353;ka J, Chl&#225;dek J, &#268;ern&#253; V. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. Crit Care. 2021;25(1):251.<pub-id pub-id-type="pmid">34274013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03680-9</pub-id><pub-id pub-id-type="pmcid">PMC8285835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermes</surname><given-names>A</given-names></name><name name-style="western"><surname>van Der Sijs</surname><given-names>H</given-names></name><name name-style="western"><surname>Guchelaar</surname><given-names>HJ</given-names></name></person-group><article-title>Flucytosine: correlation between toxicity and pharmacokinetic parameters</article-title><source>Chemotherapy</source><year>2000</year><volume>46</volume><issue>2</issue><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000007260</pub-id><pub-id pub-id-type="pmid">10671757</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy. 2000;46(2):86&#8211;94.<pub-id pub-id-type="pmid">10671757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000007260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B</given-names></name><name name-style="western"><surname>Frechen</surname><given-names>S</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C</given-names></name><name name-style="western"><surname>Holdt</surname><given-names>LM</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U</given-names></name><name name-style="western"><surname>Zander</surname><given-names>J</given-names></name></person-group><article-title>Predictors of inadequate linezolid concentrations after standard dosing in critically Ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>9</issue><fpage>5254</fpage><lpage>5261</lpage><pub-id pub-id-type="doi">10.1128/AAC.00356-16</pub-id><pub-id pub-id-type="pmid">27324768</pub-id><pub-id pub-id-type="pmcid">PMC4997846</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM, Frey L, Vogeser M, Fuhr U, Zander J. Predictors of inadequate linezolid concentrations after standard dosing in critically Ill patients. Antimicrob Agents Chemother. 2016;60(9):5254&#8211;61.<pub-id pub-id-type="pmid">27324768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00356-16</pub-id><pub-id pub-id-type="pmcid">PMC4997846</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>LGR</given-names></name><name name-style="western"><surname>Hunfeld</surname><given-names>NGM</given-names></name><name name-style="western"><surname>Kruip</surname><given-names>M</given-names></name><name name-style="western"><surname>Endeman</surname><given-names>H</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>T</given-names></name></person-group><article-title>Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients</article-title><source>Br J Clin Pharmacol</source><year>2023</year><volume>89</volume><issue>5</issue><fpage>1617</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1111/bcp.15634</pub-id><pub-id pub-id-type="pmid">36495312</pub-id><pub-id pub-id-type="pmcid">PMC9878197</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Romano LGR, Hunfeld NGM, Kruip M, Endeman H, Preijers T. Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. Br J Clin Pharmacol. 2023;89(5):1617&#8211;28.<pub-id pub-id-type="pmid">36495312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15634</pub-id><pub-id pub-id-type="pmcid">PMC9878197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolas</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorsten</surname><given-names>R</given-names></name><name name-style="western"><surname>Max</surname><given-names>K</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>M</given-names></name><name name-style="western"><surname>Markus</surname><given-names>K</given-names></name><name name-style="western"><surname>G&#252;zin</surname><given-names>S</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>SC</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>S</given-names></name><name name-style="western"><surname>Andreas</surname><given-names>P</given-names></name><name name-style="western"><surname>Kerstin</surname><given-names>H</given-names></name></person-group><article-title>Personalized antibiotic therapy for the critically Ill: implementation strategies and effects on clinical outcome of piperacillin therapeutic drug monitoring&#8212;a descriptive retrospective analysis</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><issue>12</issue><fpage>1452</fpage><pub-id pub-id-type="doi">10.3390/antibiotics10121452</pub-id><pub-id pub-id-type="pmid">34943664</pub-id><pub-id pub-id-type="pmcid">PMC8698194</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Nikolas S, Thorsten R, Max K, Patrick M, Markus K, G&#252;zin S, Oliver SC, Alexander S, Andreas P, Kerstin H. Personalized antibiotic therapy for the critically Ill: implementation strategies and effects on clinical outcome of piperacillin therapeutic drug monitoring&#8212;a descriptive retrospective analysis. Antibiotics. 2021;10(12):1452.<pub-id pub-id-type="pmid">34943664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics10121452</pub-id><pub-id pub-id-type="pmcid">PMC8698194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cousin</surname><given-names>VL</given-names></name><name name-style="western"><surname>Laudouar</surname><given-names>Q</given-names></name><name name-style="western"><surname>Le Sache</surname><given-names>N</given-names></name><name name-style="western"><surname>Mokhtari</surname><given-names>M</given-names></name><name name-style="western"><surname>Durand</surname><given-names>P</given-names></name><name name-style="western"><surname>Furlan</surname><given-names>V</given-names></name><name name-style="western"><surname>Tissieres</surname><given-names>P</given-names></name></person-group><article-title>Role of fluid status markers as risk factors for suboptimal vancomycin concentration during continuous infusion in neonates: an observational study</article-title><source>Eur J Pediatr</source><year>2022</year><volume>181</volume><issue>8</issue><fpage>2935</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1007/s00431-022-04500-0</pub-id><pub-id pub-id-type="pmid">35581390</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Cousin VL, Laudouar Q, Le Sache N, Mokhtari M, Durand P, Furlan V, Tissieres P. Role of fluid status markers as risk factors for suboptimal vancomycin concentration during continuous infusion in neonates: an observational study. Eur J Pediatr. 2022;181(8):2935&#8211;42.<pub-id pub-id-type="pmid">35581390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00431-022-04500-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>F</given-names></name><name name-style="western"><surname>Gautier-Veyret</surname><given-names>E</given-names></name><name name-style="western"><surname>Truffot</surname><given-names>A</given-names></name><name name-style="western"><surname>Chenel</surname><given-names>M</given-names></name><name name-style="western"><surname>Payen</surname><given-names>L</given-names></name><name name-style="western"><surname>Stanke-Labesque</surname><given-names>F</given-names></name><name name-style="western"><surname>Tod</surname><given-names>M</given-names></name></person-group><article-title>Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates</article-title><source>Pharm Res</source><year>2021</year><volume>38</volume><issue>3</issue><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03019-7</pub-id><pub-id pub-id-type="pmid">33686560</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Simon F, Gautier-Veyret E, Truffot A, Chenel M, Payen L, Stanke-Labesque F, Tod M. Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates. Pharm Res. 2021;38(3):415&#8211;28.<pub-id pub-id-type="pmid">33686560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-021-03019-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenoir</surname><given-names>C</given-names></name><name name-style="western"><surname>Niederer</surname><given-names>A</given-names></name><name name-style="western"><surname>Rollason</surname><given-names>V</given-names></name><name name-style="western"><surname>Desmeules</surname><given-names>JA</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y</given-names></name><name name-style="western"><surname>Samer</surname><given-names>CF</given-names></name></person-group><article-title>Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>30</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1002/psp4.12730</pub-id><pub-id pub-id-type="pmid">34791831</pub-id><pub-id pub-id-type="pmcid">PMC8752107</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2022;11(1):30&#8211;43.<pub-id pub-id-type="pmid">34791831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12730</pub-id><pub-id pub-id-type="pmcid">PMC8752107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdallah</surname><given-names>YEH</given-names></name><name name-style="western"><surname>Chahal</surname><given-names>S</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>F</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>SH</given-names></name></person-group><article-title>Drug-disease interaction: clinical consequences of inflammation on drugs action and disposition</article-title><source>J Pharm Pharm Sci</source><year>2023</year><volume>26</volume><fpage>11137</fpage><pub-id pub-id-type="doi">10.3389/jpps.2023.11137</pub-id><pub-id pub-id-type="pmid">36942294</pub-id><pub-id pub-id-type="pmcid">PMC9990632</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Abdallah YEH, Chahal S, Jamali F, Mahmoud SH. Drug-disease interaction: clinical consequences of inflammation on drugs action and disposition. J Pharm Pharm Sci. 2023;26:11137.<pub-id pub-id-type="pmid">36942294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/jpps.2023.11137</pub-id><pub-id pub-id-type="pmcid">PMC9990632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kacevska</surname><given-names>M</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>GR</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Liddle</surname><given-names>C</given-names></name></person-group><article-title>Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2008</year><volume>4</volume><issue>2</issue><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.2.137</pub-id><pub-id pub-id-type="pmid">18248309</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 2008;4(2):137&#8211;49.<pub-id pub-id-type="pmid">18248309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.4.2.137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmith</surname><given-names>VD</given-names></name><name name-style="western"><surname>Foss</surname><given-names>JF</given-names></name></person-group><article-title>Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>87</volume><issue>4</issue><fpage>488</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/clpt.2009.258</pub-id><pub-id pub-id-type="pmid">20147898</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Schmith VD, Foss JF. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin Pharmacol Ther. 2010;87(4):488&#8211;91.<pub-id pub-id-type="pmid">20147898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2009.258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vet</surname><given-names>NJ</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Tibboel</surname><given-names>D</given-names></name><name name-style="western"><surname>de Wildt</surname><given-names>SN</given-names></name></person-group><article-title>The effect of critical illness and inflammation on midazolam therapy in children</article-title><source>Pediatr Crit Care Med</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>e48</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/PCC.0b013e3181fe406d</pub-id><pub-id pub-id-type="pmid">21057365</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of critical illness and inflammation on midazolam therapy in children. Pediatr Crit Care Med. 2012;13(1):e48-50.<pub-id pub-id-type="pmid">21057365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PCC.0b013e3181fe406d</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuma</surname><given-names>M</given-names></name><name name-style="western"><surname>Makishima</surname><given-names>M</given-names></name><name name-style="western"><surname>Imai</surname><given-names>T</given-names></name><name name-style="western"><surname>Tochikura</surname><given-names>N</given-names></name><name name-style="western"><surname>Sakaue</surname><given-names>T</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>K</given-names></name><name name-style="western"><surname>Kaburaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>Y</given-names></name></person-group><article-title>Duration of systemic inflammatory response syndrome influences serum vancomycin concentration in patients with sepsis</article-title><source>Clin Ther</source><year>2016</year><volume>38</volume><issue>12</issue><fpage>2598</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2016.10.009</pub-id><pub-id pub-id-type="pmid">27836495</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Chuma M, Makishima M, Imai T, Tochikura N, Sakaue T, Kikuchi N, Kinoshita K, Kaburaki M, Yoshida Y. Duration of systemic inflammatory response syndrome influences serum vancomycin concentration in patients with sepsis. Clin Ther. 2016;38(12):2598&#8211;609.<pub-id pub-id-type="pmid">27836495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2016.10.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heffernan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Germano</surname><given-names>A</given-names></name><name name-style="western"><surname>Sime</surname><given-names>FB</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>E</given-names></name></person-group><article-title>Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?</article-title><source>Eur J Clin Pharmacol</source><year>2019</year><volume>75</volume><issue>9</issue><fpage>1219</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1007/s00228-019-02694-1</pub-id><pub-id pub-id-type="pmid">31154476</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Heffernan AJ, Germano A, Sime FB, Roberts JA, Kimura E. Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient? Eur J Clin Pharmacol. 2019;75(9):1219&#8211;26.<pub-id pub-id-type="pmid">31154476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-019-02694-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michelhaugh</surname><given-names>SA</given-names></name><name name-style="western"><surname>Januzzi</surname><given-names>JL</given-names><suffix>Jr</suffix></name></person-group><article-title>Using artificial intelligence to better predict and develop biomarkers</article-title><source>Heart Fail Clin</source><year>2022</year><volume>18</volume><issue>2</issue><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2021.11.004</pub-id><pub-id pub-id-type="pmid">35341540</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Michelhaugh SA, Januzzi JL Jr. Using artificial intelligence to better predict and develop biomarkers. Heart Fail Clin. 2022;18(2):275&#8211;85.<pub-id pub-id-type="pmid">35341540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hfc.2021.11.004</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>